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Informed consent documents for cancer research: textual and contextual factors of 
relevance for understanding 
For at pasienter eller friske personer skal kunne delta i medisinsk forskning, må de gi sitt 
informerte samtykke til denne deltakelsen. Et informert samtykke innebærer at deltakerne har 
fått grundig informasjon om hva forskningen går ut på, hva som er konsekvensene av å delta, 
og at de forstår denne informasjonen. Til slutt må de signere en samtykkeerklæring dersom de 
sier seg villig til å delta. 
Informasjonen til deltakere i forskning blir gitt både muntlig og skriftlig. Den skriftlige 
informasjonen kalles pasientinformasjonsskriv, og slike skriv er temaet for denne 
avhandlingen. Innholdet i skrivene er regulert av internasjonale etiske retningslinjer for 
medisinsk forskning og av nasjonale lovverk og retningslinjer. Regional komite for medisinsk 
og helsefaglig forskningsetikk (REK) vurderer og godkjenner pasientinformasjonsskrivet før 
forskningsprosjektet kan starte. Skrivene kan ha et komplisert innhold, og kan dermed være 
vanskelige å forstå for leserne. Målet med denne avhandlingen har vært å studere forhold som 
er av betydning for pasienters forståelse av pasientinformasjonsskriv.  
Det er viktig at pasienten forstår pasientinformasjonsskrivet, men hva betyr det egentlig å 
forstå en tekst, og hvordan skal man måle om leseren har forstått den? Vi sammenlignet 34 
studier av pasienters forståelse av informasjonsskriv, og fant at svært få av forskerne i dette 
forskningsfeltet har definert hva forståelse er. Måten forståelse er målt på, varierte også i stor 
grad fra studie til studie. Disse variasjonene gjør det umulig å sammenligne resultater av 
forskjellige studier om det samme fenomenet. Dette forhindrer at kunnskapen man kommer 
fram til i hver enkelt studie, kan brukes til å forbedre innholdet basert på hva som fungerer 
best for pasientene. 
For å undersøke hvordan pasientinformasjonsskriv er skrevet, og om de er leservennlige ble 
det foretatt to studier av informasjonsskriv. Den første var en undersøkelse av lengde og antall 
innholdselementer i 87 pasientinformasjonsskriv skrevet mellom 1985 og 2007. 
Gjennomsnittlig antall ord i skrivene var nesten tredoblet i løpet av denne perioden, mens 
antall innholdselementer var mer enn fordoblet.  
I en oppfølgingsstudie ble de ti eldste og de ti nyeste av de 87 skrivene analysert for å finne ut 
hvordan skrivemåten påvirker leservennligheten, og om skrivene dermed oppfyller sin 
funksjon som informasjon som forsøkspersonen kan bruke for å velge om han vil delta i 
forskningen eller ikke. På den ene siden var de nye skrivene mer funksjonelle enn de gamle 
fordi det var tydeligere at de handlet om forskning, og de ga dessuten leseren tydeligere 
instruksjoner om hvordan de skulle gå fram dersom de ønsket å delta. De eldste skrivene 
handlet mer om pasientens sykdom og behandling, noe som kan gjøre det vanskeligere for 
leseren å forstå at skrivet først og fremst er informasjon om forskning. På den andre siden 
inneholdt de nye skrivene flere tema og detaljer enn de gamle, noe som også kan gjøre det 
vanskeligere for leseren å forstå hovedpoenget i skrivet. De gamle skrivene hadde dessuten en 
tydeligere interaksjon mellom leser og skriver.  
Hvordan pasienter selv opplever innholdet i pasientinformasjonsskriv, studerte vi i en 
intervjustudie av lungekreftpasienter. De var mest opptatt av praktisk informasjon om sin 
egen sykdom og behandling, mens de var mindre opptatt av formell informasjon om 
forskningsprosjektet. De fleste var likevel klar over det overordna målet med forskning, dvs. å 
generere ny kunnskap som kan komme framtidige pasienter til gode.   
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Norwegian summary 
Dersom pasienter eller friske personer er villige til å delta i medisinsk forskning, må de gi sitt 
informerte samtykke til denne deltakelsen. Informert samtykke innebærer at de har fått 
grundig informasjon om hva forskningen går ut på, og hva som er konsekvensene av å delta.
Etter at de har mottatt muntlig og skriftlig informasjon, bekrefter pasientene at de er 
informert, og at de ønsker å delta i forskningen ved å signere en samtykkeerklæring. 
Den skriftlige informasjonen, pasientinformasjonsskrivet, er temaet for denne avhandlingen. 
Innholdet i slike skriv er regulert av internasjonale etiske retningslinjer for medisinsk 
forskning (hvorav den mest innflytelsesrike er Helsinkideklarasjonen utviklet av Verdens 
legeforening), nasjonalt lovverk og nasjonale og regionale retningslinjer, for eksempel fra 
regional komite for medisinsk og helsefaglig forskningsetikk (REK). REK skal også vurdere 
og godkjenne pasientinformasjonsskrivet før forskningsprosjektet kan starte.
Målet med denne avhandlingen har vært å undersøke forhold som kan påvirke pasienters 
forståelse av pasientinformasjonsskriv, og hvordan tidligere forskning har målt pasienters 
forståelse av informasjonen de har fått i samtykkeprosessen.  
Kravene til hva pasientinformasjonsskriv skal inneholde er omfattende, og man kan spørre 
seg om skriv som etterfølger alle kravene, blir så kompliserte at det blir vanskelig for leserne 
å sortere ut hva som er det viktigste budskapet. Selv om reguleringene av innhold er laget i 
pasientenes interesse, så er det tenkelig at mange av innholdselementene ikke er relevante for 
leserne. Gjennom å intervjue lungekreftpasienter fant vi at pasientene var mest opptatt av 
praktisk informasjon om sin egen sykdom og behandling, og at kontekstuelle aspekter ved 
lesesituasjonen gjorde det vanskeligere å forstå skrivene. Pasientene var mindre opptatt av 
formell informasjonen om forskningsprosessen. De fleste var likevel klar over det overordna 
målet med forskning, dvs. å generere ny kunnskap som kan komme framtidige pasienter til 
gode.
For å undersøke hvordan pasientinformasjonsskriv er skrevet, og om de er leservennlige ble 
det foretatt to dokumentanalyser. Den første var en undersøkelse av lengde og antall 
innholdselementer i 87 pasientinformasjonsskriv godkjent for bruk i studier mellom 1985 og 
2007. Analysene viste at antall ord var nesten tredoblet i løpet av denne perioden, og at antall 
innholdselementer var mer en fordoblet. Antallet innholdselementer angående såkalte 
viii
formaliteter, dvs. juridisk informasjon, finansiering, lagring av innsamlet materiale, 
erstatningsordninger, hadde økt mest.   
Problemer med å forstå et informasjonsskriv kan også skyldes skrivets lesbarhet, som i 
tidligere forskning har vært analysert vha. kvantitative lesbarhetsformler. I tillegg kan faktorer 
som tekststruktur, overskrifter og ordvalg være relevante for om skrivene er lesbare eller 
funksjonelle for de som faktisk skal lese og forstå dem. I en oppfølgingsstudie ble de ti eldste 
og de ti nyeste pasientinformasjonsskrivene av utvalget i ovennevnte studie analysert med mål 
om å finne ut hvilke tekstuelle faktorer som bidrar til funksjonelle pasientinformasjonsskriv 
og å sammenligne gamle og nye skriv i så måte. Resultatene viste at nye, lange 
informasjonsskriv ikke nødvendigvis var mindre funksjonelle enn de kortere, gamle skrivene. 
Nye informasjonsskriv var for eksempel mer rettet mot hovedtemaet i informasjonen 
(forskningen) og den viktigste handlingen som gjøres i skrivet (å spørre leseren om han er 
villig til å delta). Gamle informasjonsskriv var mer orientert mot pasientens sykdom og 
behandling, noe som ikke er funksjonelt som hovedtema i en tekst om medisinsk forskning.  
I Helsinkideklarasjonen påpekes det at legen har ansvar for at pasienten forstår informasjonen, 
men det utdypes ikke noe videre hva det egentlig innebærer å forstå informasjon om 
medisinsk forskning. En systematisk review av tidligere studier om forståelse ble gjennomført 
for å vise hvordan begrepet forståelse er definert og målt. Resultatene viste at tidligere studier 
ikke er basert på en felles definisjon av forståelse, at de fleste målemetodene er utviklet for 
hver enkelt studie, og at målemetodene er forskjellige med tanke på antall spørsmål og 
innholdet de dekker.  Dette gjør det vanskelig å sammenligne tidligere studier for å finne ut 
hva som kjennetegner effektiv informasjon til forskningsdeltakere.  
Oppsummert viser studiene i denne avhandlingen at norske pasientinformasjonsskriv har blitt 
lengre og lengre de siste årene, og at de inneholder flere innholdselementer, men at de likevel 
ikke nødvendigvis blitt mindre leservennlige. Intervjuanalyser tydet på at innholdet i skrivene 
ikke var tilpasset det som pasientene var mest opptatt av. I forskningsfeltet mangler det 
dessuten standardmetoder for å måle pasienters forståelse av informasjon, samt en felles 
definisjon ‘forståelse’.
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Summary
Participation in medical research must be completely voluntary, and a patient's or healthy 
volunteers’ decision to take part must be documented through an informed consent. Informed 
consent is the process in which the patient makes his/her decision about whether to participate 
or not based upon thorough information about the procedures of the research and the 
consequences of participating. After receiving oral and written information, the patients 
confirm that they are informed and that they are willing to participate in research by signing a 
consent form.
The written information, the informed consent document (ICD), is the topic of this thesis. The 
contents of the ICDs are regulated by international ethical guidelines for medical research (the 
Declaration of Helsinki, developed by the World Medical Association, is the most important), 
national laws, and national and regional regulations, for instance developed by the Regional 
Committees for Medical and Health Research Ethics (REC) in Norway.  An ICD is approved 
by REC before the actual reader receives it. The overall aim of this thesis has been to 
investigate factors that can affect patients’ understanding of informed consent documents, and 
how previous research has assessed patients’ understanding of consent information. 
The regulations regarding mandatory content of ICDs are extensive, and one might consider 
whether ICDs written according to the guidelines contain so much information that it 
becomes difficult for the reader to grasp the overall message. Even if lists of mandatory 
content in ICDs have been developed in the patient’s best interest, it is conceivable that 
several of the content elements are of no particular interest for the patients. Through semi-
structured interviews, we found that lung cancer patients were mostly concerned with 
information about their own treatment and prognoses, and that aspects surrounding the ICD 
reading situation might hamper the patient’s ability to understand it. The patients were less 
concerned with formal information about the research process.
In order to investigate how the Norwegian ICDs are written, and whether they are patient-
oriented, two document analyses were performed. In the first one, the length and content of a 
sample of 87 ICDs approved for use in research from 1987 to 2007 were investigated. The 
results showed that there had been a threefold increase in the number of words in ICDs during 
this period, and that the number of content elements was more than doubled. The presence of 
xformal content elements (juridical information, financing, insurance and storage of data) 
increased the most.  
However, difficulties with the understanding of ICDs might also be caused by the readability 
of the documents, which previously has been analysed by quantitative readability formulas. 
Additionally, aspects such as text structure, headings and vocabulary are possible contributing 
factors for making documents readable or functional for the actual audience. In order to 
investigate the functional readability of ICDs,  the ten oldest and the ten newest ICDs from 
the above-mentioned study were analysed in order to find out which textual characteristics 
might contribute to making ICDs readable, and to compare the readability in old and new 
ICDs. The findings indicate that even though newer ICDs are longer than the old ones, they 
are not necessarily less readable. New ICDs were, for instance, more oriented towards the 
main topic of an ICD (the research) and the main function (to ask the patient to take part). The 
older ICDs were more oriented towards the patient’s disease and treatment, which are not 
functional as main topics in an ICD for medical research.  
The Declaration of Helsinki states that the physician must ensure that the potential research 
subject has understood the information. However, no further instructions are given to clarify 
what this means and how it should be done. A systematic review was conducted on the 
concept of understanding and how patients’ understanding of research information has been 
measured. The findings confirmed that a definition of the term “understanding” is lacking, 
and there is a large degree of variation between the measuring instruments, for instance 
concerning the number of questions and the content they cover. This variation hinders 
comparisons of findings, thus making it impossible to improve ICDs based upon the results of 
these empirical studies.  
In summary, the studies in this thesis showed that Norwegian ICDs had become increasingly 
longer during the last years, and that they contain more information, bur that newer ICDs not 
necessarily less readable than old ones. The interview analysis suggested that the content in 
the ICDs were not adjusted to the patients’ preferences. In the field of research, there is also a 
lack of standardized methods for measuring patients’ understanding of information and a 
common definition of the term ‘understanding’.   
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1 Introduction 
Early in the 20th century, the American lawyer Benjamin Cardozo stated that ”Every human 
being of adult years and sound mind has a right to determine what shall be done with his own 
body” (126). This right of self-determination refers to one of the main principles of medical 
ethics: the respect for patient autonomy (16). To respect the patient’s autonomy implies that the 
physician has a duty to enable the patient to make informed decisions concerning his/her 
health care, without any kind of coercion and with sufficient understanding of the relevant 
information. 
One central implementation of respecting patient autonomy in medical care and research is 
the informed consent as a premise for patients’ decision-making. Regarding medical 
research, informed consent refers to the process in which a patient or a healthy volunteer 
declares himself/herself willing to take part in medical research after being informed about the 
relevant consequences of participation (62). The consent process includes a disclosure of both 
oral1 and written information about all the relevant aspects of the study to the eligible 
participant. The information is the basis for the patients’ decision concerning participation. 
The present thesis deals with one aspect of the informed consent process for clinical research: 
the written informed consent document (ICD). The ICD consists of information about the 
study, the request to participate, and a consent form where both the researcher providing the 
information and the one being informed have to sign the form if the patient is willing to 
participate. Thus, the ICD is also a juridical contract between the two parties.  
The content of ICDs is regulated by international and national ethical guidelines for research 
involving human participants. The most influential international ethical regulation is the 
Declaration of Helsinki, developed by the World Medical Association in 1964 (224). Derived 
from this, other ethical guidelines include more or less detailed lists of mandatory content of 
information to research participants. Also national authorities and sponsors involved in 
clinical research might make demands concerning the content of the information. Further, 
ICDs for medical research have to be approved by an ethical review board before the target 
reader, i.e. the eligible research participant (most often a patient), may receive it. The 
1 In the literature in this field, the term “verbal” is often used in the sense of oral. In this thesis, the term “oral” is 
used because the term “verbal” is rather understood as both spoken and written communication, as opposed to 
non-verbal communication.  
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members of the ethical review boards make sure that the ICD include all the relevant 
mandatory content.  
The present work on ICDs was based on a concern among clinical researchers who wrote and 
presented research information to potential participants at the oncology department at St. 
Olavs Hospital, Trondheim University Hospital, Norway. They experienced that the ICDs 
were difficult to understand for many cancer patients, particularly those who were elderly and 
in poor general health. This raised some ethical concerns. It was discussed whether regulatory 
demands in a too high degree influence the content of the ICDs in a direction of “an 
impossible“ document for the patients to cognitively process. If that was the case, we 
questioned the validity of the consent given by the patients.
The cancer researchers also noticed that the ICDs had to be much longer in 2005 than ten 
years earlier in order to get the necessary approval from the ethical review board, and started 
to wonder why. Based upon these experiences and questions, they embarked upon studying 
ICDs in order to find out: Why had they become longer? Why are they difficult to read and 
understand?  How do the readers perceive all the information? The present thesis is the result 
of the investigations addressing these questions.
An initial step in the work was to get in touch with a different field of expertise – the field of 
applied linguistics – in order to find a collaborator with a background in communication 
research. This collaborator was me, who at the time was teaching bachelor students in 
document analysis. Applied linguistics is based on the need for communication research in 
order to solve communication problems, and immediately after the first phone call, my 
enthusiasm for the ICD project arose realizing this was an opportunity to delve into a current, 
genuinely experienced communication problem: ICDs which seemed to be becoming less and 
less reader-friendly. Hopefully, our studies of ICD content, ICD language, readers’ 
perceptions and the concept of understanding might form the basis of relevant suggestions for 
how to write ICDs in a way that the patients can understand them and thus enable patients to 
make a truly informed consent to medical research.  
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2 Background 
2.1 The ethical foundation of informed consent 
Ethical theories are the foundation of both ethical principles/guidelines for medical research 
and for legal obligations related to medical research (51). In order to ensure a high quality of 
medical research and that the safety of the participants is taken care of, several international 
guidelines and recommendations have been published from the end of the Second World War 
and up until today. The guidelines include recommendations for what information should be 
conveyed to potential research subjects in the process of obtaining informed consent.
2.1.1 Principles of medical ethics 
Ethical theories of autonomy provide the moral foundation for obtaining informed consent in 
health care and research settings (51). Respect for autonomy is one of the four main principles 
of biomedical ethics, as described by Thomas Beauchamp and James Childress in their classic 
text-book, Principles of Biomedical Ethics, first published in 1979 and currently available in 
the 6th edition from 2009 (13, 16):
- respect for autonomy, i.e. the obligation to respect the decision making capacity of 
autonomous persons 
- non-maleficence, i.e. the obligation to avoid causing harm  
- beneficence, i.e. the obligations to provide benefits and to balance benefits against 
risks 
- justice, i.e. obligations of fairness in the distribution of benefits and risks (14, 15)
For the studies in this thesis, the principle of respect for autonomy is the most relevant of the 
four. Autonomy refers to self-governance. According to Faden and Beauchamp (63), the 
principle of respect for autonomy means that “[p]ersons should be free to choose and act 
without controlling constrains imposed by others”. In medical settings, this implies that 
patients should take part in the decisions – act autonomously – concerning their health care or 
their participation in research. In practice, this is for instance done by obtaining informed 
consent from patients before decisions are made in research and clinical contexts (14, 78, 158), i.e. 
decisions concerning treatment alternatives or taking part in medical research.  
Professor of Medical Ethics Raanan Gillon, who wrote a 26 part series about medical ethics in 
the BMJ in the middle of the 1980s (77), specified that to act autonomously is not just merely 
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to do what one wants, but to do it based on thought and reasoning. This implies that in order 
to be autonomous, the patient’s choices in health care and research have to be based on 
adequate information and understanding. Ideally, the thorough information disclosed to 
patients during the consent process enables them to make an autonomous choice concerning 
participation. In clinical research it is also important to balance the benefits (beneficence) and 
to avoid harm to patients (non-maleficence). These two principles are also important to have 
in mind when clinical research is planned and conducted as well as when writing the ICD. 
Principles of informed consent 
Since obtaining informed consent for a medical research consists of other aspects than merely 
informing and consenting, several attempts have been made to describe the consent process 
stepwise (16). Beauchamp and Childress, for example, present a seven-step process in the latest 
edition of Principles of Biomedical Ethics (italics added): 
I. Threshold elements (preconditions) 
1. Competence (to understand and decide) 
2. Voluntariness (in deciding) 
II. Information elements 
3. Disclosure (of material information) 
4. Recommendation of a plan 
5. Understanding (of 3 and 4) 
III. Consent elements 
6. Decision (in favour of a plan) 
7. Authorization (of the chosen plan) 
Notably, Beauchamp and Childress differentiate between "disclosure" in step 3, and 
"understanding" in step 5, recognizing that that what is disclosed is not necessarily what is 
understood (99), page 120.The present thesis deals mainly with these two steps: disclosure of 
information (in information consent documents) and the patients’ understanding of this 
information.  
The disclosure of information about the research to the eligible participants is given orally 
and written by the investigator, often the treating physician. The kind of information the 
investigator conveys, is regulated by ethical guidelines for biomedical research involving 
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human subjects, for instance the Declaration of Helsinki (224) (see section 2.1.2 for details of 
the regulations of the content of ICDs).
The ideal consent process is described in the following manner by Falagas and colleagues: 
“Appropriate information given to a competent individual will promote understanding and, in 
this regard, sensible decision making without coercion” (italics added). They immediately add 
that the reality is more complicated than this, since understanding is not a homogenous  
process, but dependent of the patient’s psychological and intellectual characteristics, and of 
his/her educational status, level of general knowledge, and personal attitudes (the latter are 
also affected by the morals and customs of the society). A further complicating aspect of the 
understanding process in a doctor-patient-setting is that “>t@he communication of medical 
information to patients is even more demanding because of the need to explain scientific 
issues with plain language” (64). Beauchamp and Childress mention additional conditions such 
as illness, irrationality, and immaturity that might limit the patients’ ability to understand 
information (14).
Further complicating the step “understanding” is trying to determine what level of 
understanding is sufficient for enabling a patient to give an informed consent. The necessary 
level of understanding has been defined rather vaguely as for instance “adequate” (16) or 
“appropriate” (165) for the eligible participant to make a voluntary decision.  
The ideal informed consent process should both convey the relevant information and promote 
understanding. However, the ethical regulations that prescribe the content of the information 
to eligible research participants do not include instructions concerning how this vast amount 
of content should be presented in order to be adequate or appropriate for the subjects. Several 
studies have addressed this topic by comparing different methods of information disclosure 
(44, 50, 99, 150, 152, 185) (see section 2.3.1 for references) without reaching a consensus of what is 
the best method of informing eligible research participants about medical research.  
                                               
2.1.2 Formal regulations of the content of ICDs 
In order to ensure that the prospective research subjects receive sufficient information about 
the research, the ethical guidelines for medical research have through the last decades listed 
more or less detailed instructions to researchers about what to tell the subjects.
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The Declaration of Helsinki is the “most widely accepted guidance worldwide on medical 
research involving human participants” (30), and written by doctors in the World Medical 
Association. Other organizations have also developed guidelines for medical research during 
the 1980s and 1990s, for instance World Health Organization (WHO), The Council for 
International Organizations of Medical Sciences (CIOMS), and the International Conference 
on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human 
Use (ICH) (guidelines presented below). The Declaration of Helsinki has been the foundation 
for the others, as illustrated in the introduction of the CIOMS Guidelines from 1993 which 
stated that “The Declaration of Helsinki (…) is the fundamental document in the field of 
ethics in biomedical research and has had considerable influence on the formulation of 
international, regional and national legislation and codes of conduct” (39). The Declaration of 
Helsinki constitutes a framework of principles which are expressed in more concrete, often 
rather detailed, terms in the other guidelines (108). However, the Declaration of Helsinki was 
not the first international guidelines of ethics for research involving human subjects – the first 
was the Nuremberg Code.  
The Nuremberg Code 
The Nuremberg Code was the first systematic international statement of the subjects’ rights 
and physicians’ obligations in medical research (5, 153). The code was developed by the judges 
who condemned the Nazi physicians for their horrifying experiments on human beings in the 
concentration camps during the Second World War (181) in order to prevent similar 
experiments in the future (5). The judgement of the 23 Nazi physicians and scientists was 
concluded with enumeration of the 10-point code of human experimentation (5). The first 
directive of the Nuremberg Code states that voluntary consent from human subjects is 
absolutely essential, and elaborates by referring to the information which is necessary for 
giving a voluntary consent: the person involved (…) should have sufficient knowledge and 
comprehension of the elements of the subject matter involved as to enable him to make an 
understanding and enlightened decision (153),  page 181.
The Declaration of Helsinki 
In 1964, the World Medical Association (WMA) – after a decade of planning, drafting and 
revising – launched the Declaration of Helsinki (217), which is still the most influential ethical 
guideline for medical research (the current version is the Seoul revision from 2008 (224)). The 
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Declaration of Helsinki is both a set of ethical precepts and a guide to the protection of human 
rights in human experimentation (108).
In the 1964 version, the mandatory information to eligible research participants was stated as 
follows:  
The nature, the purpose and the risk of clinical research must be explained to the 
subject by the doctor (217)
In the first revision, from 1975, the requirements for informed consent were significantly 
elaborated (26), and included benefits – not only risks – and also the two main participants’ 
rights: the right to refuse and the right to withdraw:
In any research on human beings, each potential subject must be adequately informed 
of the aims, methods, anticipated benefits and potential hazards of the study and the 
discomfort it might entail. He or she should be informed that he or she is at liberty to 
abstain from participation in the study and that he or she is free to withdraw his or her 
consent to participation at any time (218)
The revisions from 1983, 1989 and 1996 (219-221) did not involve any changes in the paragraph 
concerning prescribed content of the information to potential research subjects. The most 
substantial revision of the Declaration of Helsinki is the Edinburgh version from 2000 (222).
The following elements were added to the paragraph of mandatory content elements: sources
of funding, any possible conflicts of interest, and the institutional affiliations of the 
researcher. In addition, the physician’s obligation to ensure that the subject has understood 
the information is stated in the Declaration for the first time:  
After ensuring that the subject has understood the information, the physician should 
then obtain the subject's freely-given informed consent, preferably in writing (222)
The revision from 2004 (223) did not involve relevant changes concerning the informed 
consent. The latest revision of the Declaration of Helsinki from 2008 neither adds further 
mandatory content, except the broad “any other relevant aspects of the study” (224). However, 
a few details have changed in the paragraph (marked in bold in the quotation below):  
In medical research involving competent human subjects, each potential subject must 
be adequately informed of the aims, methods, sources of funding, any possible 
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conflicts of interest, institutional affiliations of the researcher, the anticipated benefits 
and potential risks of the study and the discomfort it may entail, and any other 
relevant aspects of the study. The potential subject must be informed of the right to 
refuse to participate in the study or to withdraw consent to participate at any time 
without reprisal. Special attention should be given to the specific information needs 
of individual potential subjects as well as to the methods used to deliver the 
information. After ensuring that the potential subject has understood the information, 
the physician or another appropriately qualified individual must then seek the 
potential subject's freely-given informed consent, preferably in writing. If the consent 
cannot be expressed in writing, the non-written consent must be formally documented 
and witnessed (224)
For the first time, the Declaration of Helsinki also touches upon the manner of informing, not 
just the content. However, the phrase “Special attention should be given (…) to the methods 
used to deliver the information” is rather vague and does not give the researcher specific 
recommendations about how to present the content to the eligible participants in the most 
efficient way.
CIOMS’ International Ethical Guidelines for Biomedical Research Involving Human 
Subjects
The Council for International Organizations of Medical Sciences (CIOMS) and the World 
Health Organization (WHO) initiated a new set of ethical guidelines in the late 1970s due to 
the challenges of applying the Nuremberg Code and the Declaration of Helsinki in developing 
countries (40). In 1982 CIOMS published their Proposed International Ethical Guidelines for 
Biomedical Research Involving Human Subjects (38). The Proposed guidelines are based on 
the Declaration of Helsinki, and are drawn up as specific recommendations which indicate 
how the ethical principles in the Declaration can be effectively applied, particularly in the 
developing countries (38).
The Proposed Guidelines refer to the prescribed information to research subjects as stated in 
the Declaration of Helsinki (the 1975 revision (218)) and discuss the challenges of informed 
consent related to vulnerable groups: There are many individuals, including children, adults 
who are mentally ill or defective, and those who are totally unfamiliar with modern medical 
concepts, who are incapable of giving adequate consent (38).
25
Following the two revisions of the Declaration of Helsinki in the 1980s, a revision of the 
CIOMS’ Proposed Guidelines was initiated in the late 1980s. In 1993, The International 
Ethical Guidelines for Biomedical Research Involving Human Subjects were published. This 
revision included specific and detailed recommendations of “essential information for 
prospective research subjects” in eight bullet points. It is also stated that the information 
should be given “in language that he or she is capable of understanding” (39). The list of 
essential information is far more extensive and detailed than in the Declaration of Helsinki 
and comprise the invitation to participate as a subject in research, aims, methods, duration
and benefits; risks or discomfort; alternative procedures or treatment; confidentiality; the
investigator’s responsibility to provide medical services to the subject; that therapy will be 
provided free of charge for specified types of research-related injury; compensation for 
injury; the right to refuse and to withdraw.
Ethical issues related to controlled clinical trials with external sponsors and investigators, 
carried out in low-resource countries lead to the need for a further update of the CIOMS’ 
guidelines (40). In the late 1990s, the work of a second revision were initiated, and resulted in 
the so far latest version published in 2002. In this revision the eight bullet points are extended 
to 26 points of essential information that “the investigator must provide” to the prospective 
research subject: 
1. that the individual is invited to participate in research, the reasons for considering the individual suitable 
for the research, and that participation is voluntary; 
2. that the individual is free to refuse to participate and will be free to withdraw from the research at any time 
without penalty or loss of benefits to which he or she would otherwise be entitled; 
3. the purpose of the research, the procedures to be carried out by the investigator and the subject, and an 
explanation of how the research differs from routine medical care; 
4. for controlled trials, an explanation of features of the research design (e.g., randomization, double-
blinding), and that the subject will not be told of the assigned treatment until the study has been completed 
and the blind has been broken; 
5. the expected duration of the individual's participation (including number and duration of visits to the 
research centre and the total time involved) and the possibility of early termination of the trial or of the 
individual’s participation in it; 
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6. whether money or other forms of material goods will be provided in return for the individual's 
participation and, if so, the kind and amount; 
7. that, after the completion of the study, subjects will be informed of the findings of the research in general, 
and individual subjects will be informed of any finding that relates to their particular health status; 
8. that subjects have the right of access to their data on demand, even if these data lack immediate clinical 
utility (unless the ethical review committee has approved temporary or permanent non-disclosure of data, 
in which case the subject should be informed of, and given, the reasons for such non-disclosure); 
9. any foreseeable risks, pain or discomfort, or inconvenience to the individual (or others) associated with 
participation in the research, including risks to the health or well-being of a subject’s spouse or partner; 
10. the direct benefits, if any, expected to result to subjects from participating in the research 
11. the expected benefits of the research to the community or to society at large, or contributions to scientific 
knowledge; 
12. whether, when and how any products or interventions proven by the research to be safe and effective will 
be made available to subjects after they have completed their participation in the research, and whether 
they will be expected to pay for them; 
13. any currently available alternative interventions or courses of treatment; 
14. the provisions that will be made to ensure respect for the privacy of subjects and for the confidentiality of 
records in which subjects are identified; 
15. the limits, legal or other, to the investigators' ability to safeguard confidentiality, and the possible 
consequences of breaches of confidentiality; 
16. policy with regard to the use of results of genetic tests and familial genetic information, and the 
precautions in place to prevent disclosure of the results of a subject's genetic tests to immediate family 
relatives or to others (e.g., insurance companies or employers) without the consent of the subject; 
17. the sponsors of the research, the institutional affiliation of the investigators, and the nature and sources of 
funding for the research; 
18. the possible research uses, direct or secondary, of the subject`s medical records and of biological 
specimens taken in the course of clinical care (See also Guidelines 4 and 18 Commentaries); 
19. whether it is planned that biological specimens collected in the research will be destroyed at its 
conclusion, and, if not, details about their storage (where, how, for how long, and final disposition) and 
possible future use, and that subjects have the right to decide about such future use, to refuse storage, and 
to have the material destroyed (See Guideline 4 Commentary); 
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20. whether commercial products may be developed from biological specimens, and whether the participant 
will receive monetary or other benefits from the development of such products; 
21. whether the investigator is serving only as an investigator or as both investigator and the subject`s 
physician; 
22. the extent of the investigator's responsibility to provide medical services to the participant; 
23. that treatment will be provided free of charge for specified types of research-related injury or for 
complications associated with the research, the nature and duration of such care, the name of the 
organization or individual that will provide the treatment, and whether there is any uncertainty regarding 
funding of such treatment. 
24. in what way, and by what organization, the subject or the subject`s family or dependants will be 
compensated for disability or death resulting from such injury (or, when indicated, that there are no plans 
to provide such compensation); 
25. whether or not, in the country in which the prospective subject is invited to participate in research, the 
right to compensation is legally guaranteed; 
26. that an ethical review committee has approved or cleared the research protocol. 
The ICH guideline for Good Clinical Practice 
The International Conference on Harmonisation of Technical Requirements for Registration 
of Pharmaceuticals for Human Use (ICH) was convened by the EEC (today’s EU) in 1990 in 
order to harmonize the regulations and guidelines for drug development from different 
national authorities and pharmaceutical industry in Europe, Japan and the US (with WHO, 
Canada, Australia, and the Nordic countries as observers). The ICH Guideline for Good 
Clinical Practice (GCP), based on principles originating in the Declaration of Helsinki, was 
finalized in 1996 (62) (and has to our knowledge not been modified since then).  
The ICH GCP guideline also includes a list of mandatory content of information for potential 
research participants. In the introduction to this list, the ICH GCP, as the only guideline, 
refers specifically to giving information both orally and in writing: “Both the informed 
consent discussion and the written informed consent form and any other written information 
to be provided to subjects should include explanations of the following”: 
(a) That the trial involves research 
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(b) The purpose of the trial. 
(c) The trial treatment(s) and the probability for random assignment to each treatment. 
(d) The trial procedures to be followed, including all invasive procedures. 
(e) The subject’s responsibilities. 
(f) Those aspects of the trial that are experimental. 
(g) The reasonably foreseeable risks or inconveniences to the subject and, when applicable, to an embryo, fetus, 
or nursing infant. 
(h) The reasonably expected benefits. When there is no intended clinical benefit to the subject, the subject 
should be made aware of this. 
(i) The alternative procedure(s) or course(s) of treatment that may be available to the subject, and their 
important potential benefits and risks. 
(j) The compensation and/or treatment available to the subject in the event of trial-related injury. 
(k) The anticipated prorated payment, if any, to the subject for participating in the trial. 
(l) The anticipated expenses, if any, to the subject for participating in the trial. 
(m) That the subject’s participation in the trial is voluntary and that the subject may refuse to participate or 
withdraw from the trial, at any time, without penalty or loss of benefits to which the subject is otherwise 
entitled. 
(n) That the monitor(s), the auditor(s), the IRB/IEC, and the regulatory authority(ies) will be granted direct 
access to the subject’s original medical records for verification of clinical trial procedures and/or data, 
without violating the confidentiality of the subject, to the extent permitted by the applicable laws and 
regulations and that, by signing a written informed consent form, the subject or the subject’s legally 
acceptable representative is authorizing such access. 
(o) That records identifying the subject will be kept confidential and, to the extent permitted by the applicable 
laws and/or regulations, will not be made publicly available. If the results of the trial are published, the 
subject’s identity will remain confidential. 
(p) That the subject or the subject’s legally acceptable representative will be informed in a timely manner if 
information becomes available that may be relevant to the subject’s willingness to continue participation in 
the trial. 
(q) The person(s) to contact for further information regarding the trial and the rights of trial subjects, and whom 
to contact in the event of trial-related injury. 
(r) The foreseeable circumstances and/or reasons under which the subject’s participation in the trial may be 
terminated. 
(s) The expected duration of the subject’s participation in the trial. 
(t) The approximate number of subjects involved in the trial. 
Norwegian regulations 
Clinical researchers in Norway have probably most often written their ICDs in accordance 
with various instructions received from Regional Committees for Medical and Health 
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Research Ethics (REC). Thereafter, the committee reviewed and recommended (or not) the 
ICDs before they could be used in the consent process2.
In the review process, the REC might have given the researcher/author instructions concerning 
how to modify the content or wording of the ICD, and the researcher/author has been strongly 
advised to follow the instructions before giving the ICD to the eligible research participants. 
Thus, the Norwegian RECs have had a dual role regarding informed consent documents: (1) 
They have developed instructions for how the ICDs should be written, and (2) They 
recommend/approve the ICDs before the eligible research participants receive them.  
Additionally, other agencies beyond the REC might have given the researcher/author 
feedback concerning the content and design of the ICD. Dependent of the type of study, the 
Norwegian Medicines Agency, the Norwegian Directory of Health, Norwegian Social Science 
Data Services (NSD), the Data Inspectorate, and the Ministry of Health and Care Services 
might have been involved in the review process (personal communication with Arild Hals, 
secretariat of REC Central Norway and Sigmund Simonsen, Department of Health and 
General Practice, NTNU). 
2.2 ICDs as part of the consent process 
The informed consent documents (ICDs) are only one part of a communication process called 
the consent process. The aim of the process is to convey sufficient information about the 
study to the eligible research participant, in order to enable him/her to make a truly informed 
consent to participate or to refuse. There are several challenges related to achieving the aim of 
the consent process. The communicating actors in the process often have dual roles: The 
physician is both a physician and a researcher and the patient is both a patient and a potential 
research participant, something which might be confusing. Further, in the case of clinical 
trials, the information about the trial has to be disclosed in a situation where the patient’s 
disease quite often is progressing, and his/her situation is characterized by anxiety, despair or 
confusion. The patients’ cognitive capacity might be reduced due to the disease. For many 
patients, this is obviously not the optimal point of time for acquire new knowledge about a 
medical study – a topic that is unfamiliar for many patients.  
2 After the implementation of the Health Research Act in 2009, REC approves the ICDs, not only recommends, 
see section 6.3. 
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In clinical settings, the oral communication between physicians and patients are also a very 
important part of the consent process. The patient is often asked to join a study during an oral 
consultation before he/she receives the ICD. However, the oral information is not regulated to 
the same extent as the written ICD, since, for instance, no approval is needed for oral 
information. The regulations of content and the consequences of the regulations for the ICDs 
are the starting point for the studies in this thesis. In this section, the ethical foundation of the 
informed consent will be presented, mainly focusing on autonomy. Thereafter, the 
development of ethical regulations of the content of ICDs will be presented.  
2.3 Previous research on informed consent documents (ICDs) 
There are currently a vast number of ethical regulations available that prescribe what kind of 
information eligible research participants should receive in the consent process. The 
regulations seem to have become increasingly detailed during the last two decades. The 
regulations are developed with the aim of ensuring that the consents are truly informed. Still, 
the question of whether the information is actually understandable for patients has been the 
subject of a considerable number of empirical studies. The empirical studies in the field can 
be divided into three main types: (1) studies of whether the patients understand the 
information about the study (64, 72), (2) studies of participants’ satisfaction and information 
preferences concerning the entire consent process or parts of it (69, 205), and (3) studies of the 
documents readability, length and/or and content (12, 179). Combinations of outcomes are 
common in previous studies, for instance understanding and readability (22) and patients’ 
experiences and readability and length of ICDs (204). The three directions of research are 
presented in separate sections below.
2.3.1 Participants’ understanding of ICDs 
Several previous studies have been conducted in order to measure research participants’ 
understanding of consent information (8, 11, 18, 46, 48, 61, 66, 67, 80, 85, 92, 94, 98, 111, 114, 115, 118, 128, 130, 156, 
162, 166, 170, 174, 175). A review by Falagas and colleagues (64) evaluating patients’ understanding 
of several aspects of the informed consent process, including studies from 1961 to 2006, 
concluded that participants may not clearly understand the investigative nature of clinical 
research. They found, for instance, that participants had an adequate comprehension of the 
aim of the research in only half of the studies that provided relevant data. In an updated 
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review including studies from 1996 to 2007, Cohn and Larson confirmed previous findings 
concerning research participants’ limited level of understanding consent information (35).
Cohn and Larson pointed out that despite an increase of regulations and attention to the 
consent process, no improvement in comprehension of informed consent could be detected, 
even in more recent studies.  
The studies of patients’ level of understanding are frequently based upon “the fact” that 
previous studies have shown research participants’ poor understanding of information, for 
instance: “One area that is consistently identified in the literature as being a problem is that 
patients often do not understand key components of the research trial” (2), and “many studies 
have shown that clinical research consent forms are too difficult for patients to understand” 
(52).  However, when looking into the specific studies, it seems more precise to describe the 
results in previous research as Griffin and colleagues did: “Previous studies report mixed 
results about how much information study participants actually can read, understand and 
retain” (85). In quite a few studies, the respondents were found to have a fairly good 
understanding of the information they had received during the consent procedures (11, 18, 92, 109, 
111, 114, 175, 200).
Other studies showed that patients had high level of understanding of some aspects of the 
information and poor understanding of other aspects (46, 49, 61). For instance, Criscione and 
colleagues found that all the respondents understood that the trial was a medical experiment, 
and that a majority answered correctly regarding placebo and masking and also regarding 
voluntariness and the right to withdraw, while they showed less understanding of 
randomization and risks (46). A low level of understanding of risks was previously found in the 
study by Estey and colleagues, who also found that almost half of the participants did not 
have a clear understanding of the concept of confidentiality (61). On the other hand,  in the 
study by Daugherty and colleagues, a majority of the participants remembered one or more of 
the risks, while few were able to state the research purpose (49). The participants' in Daugherty 
et al's study were eligible for phase I trials. A review of consent consultations in phase I trials 
confirmed that the majority of the participants answered the question about the aim of the 
study correctly (42). On the whole, only a few previous the studies of participants’ 
understanding showed overall poor participant understanding (8, 166). Riecken & Ravich found 
that only about 10 % of the participants could give a lucid account of the purpose of the study 
(166) and Appelbaum and colleagues found that the majority of the participants manifested 
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some degree of misconception about personal benefit and individualized decision about their 
care (8)
Comparisons of different methods for conveying information 
A subcategory of the studies of understanding is randomized trials in which the effect of 
different methods of providing information have been compared in order to examine which 
method was most effective in promoting the participants’ understanding. The interventions 
have involved either modifications of the informed consent documents (2, 22, 23, 27, 44, 50, 52, 60, 134, 
149, 150, 160, 171, 190, 197, 198, 227) or other information interventions, most often the use of 
multimedia such as videotapes or DVDs (99, 109, 152, 185, 192, 200, 213, 230). The results of such 
studies are compared thoroughly in review articles (1, 35, 54, 56, 72), with different approaches and 
conclusions. The main conclusion in the systematic review by Flory and Emanuel (72) was that 
to spend more time talking to a study member or neutral educator appeared to be the most 
efficient available way of improving participants’ understanding, while Edwards and 
colleagues (56) concluded in a similar, but broader manner that “more information results in 
greater knowledge”. Other interventions, such as multimedia interventions or enhanced ICDs, 
did not lead to significantly increased level of understanding (72). On the other hand, in the 
review by Dunn and Jeste, the authors concluded that 11 of 16 studies were “positive”, since 
they demonstrated increased understanding among participants in the intervention groups.
The differences between these reviews were to a certain degree caused by different aims in 
the reviews, some variations on which studies have been included and the time period for 
inclusion. However, the main cause of the different review results was that the review authors 
had not interpreted the results of the included studies in the same way, and that they had not 
assessed the quality of the studies with the same degree of thoroughness. For instance, the 
results of two of the studies characterized as “positive studies” by Dunn and Jeste (22, 54, 227)
were questioned by Flory and Emanuel since they evaluated simulated consent processes (72).
Further, two studies of a supplementary video intervention (76, 208) were interpreted as 
“positive studies” by Dunn and Jeste (54) while Flory and Emanuel included these two studies 
in their overall conclusion regarding multimedia interventions: they “often failed to improve 
research participants’ understanding” (72).
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Why then, could two reviews make the opposite conclusions about the results of the same two 
studies? The so-called “positive” result in the two abovementioned studies regarded long-term 
retention of the information. No differences were found between the intervention groups and 
the control groups regarding the comprehension scores directly after the consent information 
had been disclosed. Flory and Emanuel commented in a footnote that long-term improvement 
in retention showed that the intervention improved memory and not comprehension at the 
time of information disclosure (72).
Weaknesses in the studies concerning a lack of consistence regarding definition, 
operationalization and assessments, especially the confusion of recall/memory with 
understanding (1, 54, 56, 143) has been discussed by other authors of systematic reviews as well, 
and Edwards and colleagues stated that “[s]imple recall of information is potentially 
misleading, since memory per se is an imperfect indicator of understanding” (56).
Two interview studies illustrate the differences between recall and understanding, one by 
Katie Featherstone and Jenny Donovan (66, 67) and one by Claire Snowdon and colleagues (187).
In both, the research participants’ understanding and recall of randomization was explored. 
The results in both studies showed that the participants had a fairly good recall of the 
allocation process or seemed familiar with the terms “random” and “randomization”, while 
they on the other hand revealed uncertainty and misunderstanding of the same terms. Patricia 
Agre and colleagues referred to the lack of consistence regarding the “gold standard” of 
understanding and summarized basic unanswered questions in the field in 2003:
[W]hat is or should be the “gold standard” of understanding? What should we expect 
 people to know? Many of the intervention studies used knowledge quizzes to assess 
 understanding, but what should qualify as adequate performance on such a quiz? […] 
 Do scores on knowledge quizzes actually reflect and understanding of the information 
 provided? Are all of the elements of equal importance, and if not, which are most 
 important? (1)
2.3.2 Participants’ satisfaction and information preferences in the informed 
consent process 
The other main direction in the field of research on the information given in the consent 
process, is the studies of participants’ satisfaction and preferences  which also are crucial 
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aspects of a successful consent process. These studies have been aimed at a variety of aspects 
regarding the information presented.  
Studies have included subjective evaluations of understanding (i.e. evaluation of one’s own 
understanding) of the information / the ICD (69) and participants’ evaluations of various 
aspects of the consent process, for instance overall satisfaction with the information or 
evaluation of the quality of information (114, 164, 201, 206), whether the information was perceived 
as useful in the decision-making process (93, 162), and also evaluations of the amount of 
information (19, 69, 132, 156, 164, 201, 209) and the time provided to consider the decision (19, 20).
Readers’ preferences concerning the description of randomization have also been addressed 
(113).
Overall, research participants have reported to be satisfied with the information process and 
disclosure, and they often prefer to be thoroughly informed (37, 73, 209). However, in two 
studies, the results showed increased level of anxiety after receiving thorough information 
about all relevant aspects of the study (185) and similar lower level of anxiety when receiving 
an easy-to-read ICD (44). Even if many patients express a preference for detailed information 
in the informed consent process, the large amount of information might still cause 
misunderstandings or problems sorting out the main message of the information, supported by 
a tendency for patients to overestimate their own understanding (115).
Fewer studies have been oriented towards the participants’ needs and preferences concerning 
the content of information (i.e. studies of what the patients want to know before making a 
decision) (28, 151, 194). The reasons for investigating information needs have partly been related 
to recruitment aspects, i.e. what information is important for patients who consents (194) or 
how much information do eligible participants prefer (6), and partly to basic ethical aspects of 
research with human participants, for instance the need to include “patient satisfaction” as a 
necessary condition for quality the informed consent process (205). In their study of subjects’ 
information needs in clinical pain research, Casarett and colleagues described the ICD 
authors’ challenges related to fulfilling the content requirements. The requirements allow the 
writers of ICDs to disclose a large amount of information to the subjects eligible for a medical 
study. However, there is uncertainty about which part of this information the patients actually 
want. For instance, it is not known which risks or potential benefits that are important for 
patients when they make their decision about participating in clinical pain research. Neither is 
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it known how much information the patients want to receive. Casarett et al discovered that the 
patients had different concerns about the study: about contingency plans, about addiction to 
opioids and about study-related changes in medication, dose, or dosage schedule. The authors 
claim that by adjusting the information to these concerns, the recruitment to pain research 
might increase.(28).
As far as we know, there is only one previous study in which patients have been asked to 
indicate what contents they found pertinent for a decision to agree to or refuse participation 
(194). The patients in this study indicated what they found to be pertinent by underlining the 
most relevant information in a hypothetical ICD. The result showed that the ideal consent 
process of patients “weighing” the pros and cons of participation before reaching an 
autonomous decision, is not the picture of an actual consent process. Only 13 of the 50 
participants underlined both benefits and risks as important information for their decision. 
This indicated that a substantial number of patients did not weigh risks and benefits as part of 
their decision-making process. The results of the study further showed that patients assigned 
very different meanings to the same information (194).
Even though patient preferences and experiences regarding the consent process has been the 
topic of quite a few studies, no previous study have investigated how actual eligible research 
participants’ assess the mandatory content of the information in the consent process. As 
presented in section 2.1.2, ethical regulations of medical research have been updated and 
expanded during the 1980s and 1990s and new regulations have been published, resulting in a 
steady increase of the amount of instructions about what to tell the patients in the consent 
process. The increasing amount of content regulations makes it relevant to question which 
content elements are most relevant for the patients who are supposed to use the ICDs as part 
of their decision-making process. The reader’s evaluation of the content would be of 
relevance for how to organize the topics of ICDs so that the information is made relevant for 
the readers and at the same time covers all the necessary content.  
2.3.3 Document analysis of ICDs
The third main direction within the field of research in information in consent processes is 
analysis of the documents themselves. For more than 25 years, researchers have noted that 
informed consent documents might be written inappropriately (87, 88, 179). In previous research, 
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one might identify two main approaches to document studies of ICDs: (1) readability studies 
and (2) content analyses.  
Readability studies  
Readability is what makes some texts easier to read than others, and is usually measured with 
quantitative instruments based on the use of long and short words and/or word familiarity and 
frequency. Since the beginning of the 20th century, a large amount of formulas have been 
developed for testing of readability, and approximately 200 formulas are available today (53).
When analysing documents by use of readability formulas, the results are numbers on a scale 
which indicates whether the documents are easy or difficult to understand, for instance a 
Flesch Reading Ease Formula scale ranging from 0 to 100 – the higher the number, the easier 
the text is to read (71).
The readability of ICDs has been measured in several previous empirical studies. The most 
frequent way of reporting the results are the so-called “grade level”, i.e. a number indicating 
the years of education needed to be able to understand the document. In 20 observational 
studies of readability conducted between 1989 and 2007, identified through a MEDLINE 
literature search, the grade level was over 13 in nine of the studies (equivalent to about the 
first year of college/university in the USA ) and over 10 in all but one (about junior high in 
the USA) (12, 25, 31, 74, 79, 82, 87, 90, 97, 104, 129, 131, 142, 155, 167, 179, 183, 196, 210, 211).
The scores in the mentioned readability studies are not directly comparable, since the results 
would be different by the use of the Flesch-Kincaid Grade Level Index (FKGL) compared to 
Fry Graph Readability Formula (the Fry graph) or the Gunning’s Fog Index Readability 
Formula (the Fog index). The study by Christopher and colleagues, the result showed a 12th-
grade reading level using the FKGL, a 13.9th-grade reading level when using the Fry graph, 
and a 14.5th-grade reading level when using the Fog Index (31).
However, the results indicate that based on quantitative readability indexes, the ICDs for 
clinical research are written on a level that is far too complicated for the majority of the 
population to understand. The International Adult Literacy Survey (IALS) was conducted in 
several countries between 1994 and 1998. The results showed that low literacy skills were not 
found only among marginalised groups but also among “significant proportions of the adult 
populations in all countries surveyed. Between one-quarter and three-quarters of adults fail to 
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attain literacy Level 3, considered by experts as a suitable minimum skill level for coping 
with the demands of modern life and work.”(154). The recommended level for provision of 
patient medical information is at US grade 6 (11–12 years) (214).
There is, however, no scientific evidence that ICDs written at a high readability level actually 
would be better understood by the readers (102). Mark Hochhauser has pointed to the large 
amount of mandatory information in the ICDs as a more plausible source of the problems of 
understanding than words and reading grade levels (102). It is relevant to investigate how the 
increasing amount of content regulations (section 2.1.2) has affected the ICDs.
Content, terminology and text structure 
Some researchers within the field of consent information have recently turned their focus 
towards content and language analyses in addition to, or as an alternative to, traditional 
readability analysis. Content analyses of documents involves using or developing a set of 
categories and to count the number of instances that fall into each category (182), page 159.
Content analyses of ICDs have typically used some kind of recommendations for content as a 
basis for the predefined categories – either one or a few elements, or a whole list (12, 107, 183, 204, 
210). The three oldest of these studies showed that basic elements were omitted in the 
documents (107, 183, 210) while the two newest studies showed that the ICDs mostly contained 
the necessary information (12, 204). For instance, in Hull et al.'s content analysis of ICDs for 
genetic research, they conclude that there were examples of critical omissions and 
unnecessary inclusions in the over 250 documents included. On the other hand, Verastegui, in 
her analysis of Mexican ICDs found the all the ten ICDs included all the basic elements 
required by international ethical guidelines. 
The terminology in ICDs has been investigated in different ways. For instance, identification 
of which terms were used for the subject, the investigator and the study agent was done in two 
studies of ICDs from gene transfer studies (120, 121). The results showed that treatment 
terminology (“patient”, “doctor” or “treatment”) were often used instead of or 
interchangeably with research terminology (“research subject”, “investigator” or “study 
drug”) in the ICDs. 
The main result in the study by King and colleagues was that potential benefits in the ICDs 
were not presented in a clear and unambiguous way. The analysis revealed vagueness, 
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inconsistency, and overstatement, and thus it is probable that the readers might misinterpret 
what to expect from taking part in the research (121). Ambiguous language might cause 
confusion concerning what to do, about who is going to do what and about the implications of 
participating, for instance the degree of personal benefit. 
Mark Hochhauser has looked into potential difficult words used in ICDs, another aspect that 
is not covered by traditional readability formulas: “those formulas don’t specify specific 
words or phrases that average readers might find hard to understand” (101). As 
recommendations to IRB members, Hochhauser suggested alternative words and phrases for 
several common ICD terms, for instance “to swallow a pill” instead of “oral administration”, 
“you might have these six problems” instead of “foreseeable risks and discomforts, and “will 
not cure” instead of “no medical benefits”.  
Few studies of ICDs have included the structure of information in the analysis, i.e. the 
placement of the information in the text and/or use of headings. Horng and colleagues (105)
pointed to the impact of placing relevant information in the beginning of the document. In 
about 85% of the ICDs in their study, a statement indicating that the study was research was 
considered to be "prominent" based on its placement in the beginning of the document (and 
that it was easy to identify and repeated). Strategic placement of information is way of 
highlighting important information. To place important information in the beginning of a 
document is a way of framing the subsequent information, i.e. indicating for the reader how to 
interpret the rest of the document (195).
The study by Sandra Philipson and colleagues (163) is one of very few studies that have made 
use of a broad framework including other aspect of readability than word length, sentence 
length and content. The Readability and Processability Form (RPF) used for analysis include 
the Fry readability scale, but also 19 other areas of analysis. The RPF is based on reading 
comprehension theories and developed to evaluate areas of comprehension that critical for 
reading and understanding expository material. Areas included in the study were for instance 
vocabulary related elements (presence of difficult terms, the use of exemplifications, 
highlighting of important terms by italics or bold), the need to state main ideas clearly, to use 
familiar syntactic patterns and to address the reader by personal pronoun rather than in third 
person. In order to help the reader understanding the information, it was considered helpful if 
the text enabled the reader to create vivid mental images of the procedures used in the 
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described study. The results showed that many ICD were written more appropriate for a 
medical audience than the lay public because they were written in a technical style that lead to 
a loss of personal tone. Further, the ICDs were found to probably cause confusion due to 
ambiguous sentences and overall lack of clarity.
The content of ICDs is included in increasingly more studies, while other textual aspects still 
are limitedly investigated. In the search for answers to the overall question - how to write 
understandable ICDs  it is necessary to investigate several textual characteristics of ICDs, 
such as structure and vocabulary.
2.3.4 Summary 
Previous research in the field of informed consent and readers understanding of the 
information in consent processes have shown that research participants in some cases do not 
have a sufficient level of understanding of the information to be able to give a valid consent to 
participation. However, it has also been pointed out that the studies measuring patients’ 
understanding has been very heterogeneously conducted, something which makes it difficult 
to compare previous studies. There is a need for systematizing the methodologies in the field 
in order to conduct future studies of understanding in a more standardized manner.  
The number of guidelines for consent information and their level of detail have been steadily 
increasing during the past years, and in the light of this it is relevant to investigate both 1) 
how actual readers relate to all the information and 2) how the informed consent documents 
have changed during the years of expansive guidelines. Since most of the previous analysis of 
ICDs have made use of quantitative readability formulas, there is furthermore a need for 
broadening the analytic approaches that take into consideration aspects such as who is the 
ICD actually written for, what is the main message and function of the ICD, and how should 
this be conveyed in a comprehensible manner to the reader? 
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3 Aims of the study 
The overall aim of this thesis was to investigate factors that can affect patients’ understanding 
of informed consent documents, and how previous research has assessed patients’ 
understanding of consent information 
In order to investigate this, we conducted four separate studies with the following research 
questions:
- Which contents of the ICDs did the patients consider relevant or important? (Paper I) 
- How did the patients assess the amount of information in the ICDs  did they find any 
of the information redundant, or did they want additional information? (Paper I) 
- How has ‘understanding’ been defined in empirical studies of trial participants’ 
understanding of consent information? (Paper II) 
- How has ‘understanding’ been measured in empirical studies of trial participants’ 
understanding of consent information? (Paper II) 
- Has the length and amount of content elements of ICDs for oncological trials 
increased from 1987 to 2007? (Paper III) 
- If length and amount of content elements have increased in the ICDs, what 
information has been added during the period 1987 to 2007? (Paper III) 
- What textual characteristics contribute to functional linguistic readability of ICDs? 
(Paper IV)
- How has functional linguistic readability of ICDs developed during the last 20 years? 
(Paper IV)
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4 Material and methods 
Descriptions of the samples and methods for each study are presented separately below. (An 
overview is given in table 1, see attachment on the next page).   
4.1 Paper I: Interview study
4.1.1 Participants and ICDs 
The patients participating in the interview study (the ‘POP’ trial) were eligible for a 
randomized, phase III study by the Norwegian Lung Cancer Group comparing pemetrexed 
plus carboplatin versus gemcitabine plus carboplatin as first line chemotherapy for patients 
with stage IIIB/IV non-small cell lung cancer (the ‘PEG’ trial), at St. Olavs Hospital, 
Trondheim, Norway (86). The patients were eligible for the POP trial if they fulfilled all the 
inclusion criteria for the PEG trial, except “signing of consent form”, since they signed 
consent form for the PEG trial after they had participated in the POP trial. Further inclusion 
criteria were: chemotherapy naïve, over 18 years old and a WHO performance status of 0-2 
(86), indicating that patients were self-caring and ambulatory, but not necessarily able to carry 
out work activities.  
The patients were included between September 2005 and July 2006. After being informed 
about the PEG trial by their physicians, the eligible participants were also asked if they were 
willing to take part in an interview study, and given a separate informed consent document for 
this. If willing to participate, the patients signed a separate consent form for the POP trial. In 
the POP ICD, the patients were informed that the investigators wanted to find out what 
information the patients would prefer to read in an ICD for a clinical trial.  
The POP trial was a randomized, explorative study in which patients’ perceptions of two 
versions of an ICD were compared. The ICD described a clinical trial for which the patients 
were actually eligible (the PEG trial). A shortened version of the ICD for the PEG trial was 
developed for this study. The original ICD consisted of 1118 words and was approved by 
Regional Committee for Medical and Health Research Ethics (REC) in Central Norway in 
2004. The shortened version contained 508 words and was based on a shorter ICD approved 
for a similar study ten years earlier. 
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Both versions of the ICD consisted of information about the treatment and research 
procedures. The original ICD were longer mainly due to more information about: 
- what will happen to the collected data (storing, deleting, confidentiality and 
publishing)
- who is responsible for the study
- funding of the study 
- approving authorities; information termed “formalities”. 
The distribution of the main categories of content in the two versions of the ICD is given in 
table 2
Table 2 Medical aspects and formalities in the two versions of the ICD used in the POP trial 
 The original document The shortened document 
The medical aspects 823 words 458 words 
The formalities 259 words (23.2 %) 50 words (9.8 %) 
Other 36 words  
Sum 1118 words 508 words 
4.1.2 Semi-structured interviews 
The included patients were randomly assigned to two equal groups: one group received the 
original consent document, and one group received the shortened version. After reading the 
standard or the shortened ICD for the PEG trial, the patients participated in semi-structured 
interviews. All the interviews were undertaken by the same interviewer, the first author, who 
was an applied linguist, i.e. was not health professional or involved in the treatment of the 
patients. The interviews took place at a minimum of 90 minutes and a maximum of 30 hours 
after the patient had received the ICD. Twenty-one of the interviews were performed at the 
hospital, and most of them in the patient’s room (often while the patient was lying or sitting in 
bed), while some were performed in a sitting area nearby. The last interview was performed in 
the patient’s own home. The patients had the ICD available during the interview. All patients 
later read and signed the original ICD before they were enrolled in the PEG trial. 
The interview guide consisted of six questions, which were meant to be a thematic guide for 
the interviewer, not a list to follow strictly from start to end. The questions were intended as 
46
initiatives to discussions with the patients. Follow-up questions were used for clarifications 
and elaborations. The three first questions concerned the amount of information in the ICDs 
the patients had read: whether the information was sufficient, whether some information 
could be removed and whether the patients wanted some additional information. After the 
third question, a brief explanation was given by the interviewer about the regulations of 
content in ICDs and the mandatory information about research formalities and the fourth 
questions concerned the patients’ information needs concerning these formalities. The fifth 
question addressed the patients’ evaluation of the language in the ICD, and the final question 
addressed what the patients found to be the most important factors for their decision-making. 
Eighteen of the interviews were audio taped and transcribed verbatim by the first author. 
Technical problems made the audio tapes unusable for the remaining three interviews, but 
thorough notes had been taken during and/or after these interviews.
4.1.3 Qualitative content analysis 
The interviews were analysed through qualitative methods of content analysis; these methods 
comprised subjective and systematic interpretations of the content of text data (here 
transcriptions) through identification and categorization of essential themes and patterns (106, 
177, 226). The data were analysed and interpreted by the principle investigator and one of the co-
authors.
The preparation phase of the analysis comprised reading and re-reading of the transcribed 
interviews in order to get an overall impression of what was said, both answers to the 
interview questions and other topics that were brought up. Brief summaries of each interview 
were written, and both the summaries and the recordings were used in the further analytic 
process.
The analysis was based on both deductive (predefined) and inductive categories (139). The 
deductive categories were developed based on the research questions of the study, which were 
applied on the text (transcriptions). The inductive part of the analysis comprised deriving 
categories from the data itself, i.e. the themes the informants themselves brought up, not 
decided in advance by the investigators (58). The inductive categories included both topics that 
were related to the research question and topics that were related to the context of the 
patients’ experiences which were relevant for interpreting how the patients understood the 
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ICD and the situation. Both the deductive and the inductive categories were developed 
through discussion between the authors.  
The deductive content analysis comprised the first part of the analysis. The deductive 
categories concerned the patients’ perceptions of content in the ICDs. Operationalization of 
the research questions were manifested in the interview guide, and therefore the guide was 
used as a preliminary categorisation matrix (58). The application of the matrix implied to apply 
to identify the patients’ answers, and to code and systematize them (139). During the process, 
the topic “language in ICDs” was removed from the analysis, due to practically no 
information yielded about this from the participants. 
The deductive phase also involved to compare the results from the two groups, those who 
read the original ICD and those who read the shortened. No considerable differences were 
identified concerning how the patients assessed the content of the ICDs, and therefore the 
second part of the analysis was based on the all the interviews as a whole.
The second part of the analysis had an inductive approach, meaning that categories were 
developed based on topics that emerged during the interviews (58). Overall, the basis for the 
inductive categories are also the research questions and the theoretical background of the 
study (139). The inductive categories in the POP interviews were developed from what the 
patients said concerning relevant contextual aspects that might illustrate why they related to 
the ICD the way they did. Contrary to the deductive phase, the coding process in this phase 
was more open, including to extract relevant headings related to all the content of the 
interviews (58). Such headings were further used for developing categories relevant for 
describing the phenomenon of investigation, i.e. the patients’ evaluation of ICDs.
4.2 Paper II: Systematic review 
Paper II is a systematic review of previous research concerning evaluation, testing or 
measurement of regular trial participants’ understanding of information provided during the 
consent procedures for medical research.
Relevant empirical, original research studies were identified through a literature search in four 
databases: MedLine, Embase (1980–2007 week 39), ISIWeb of Science, and PsycINFO. The 
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search terms used were (informed consent OR consent forms) AND (clinical trials OR clinical 
research) AND (comprehension OR understanding). The hand search was performed by 
searching the reference lists of all the included papers, and of relevant review papers. The 
literature search yielded 1139 papers. 
Studies were included if: 
- the participants were eligible for, or already participating in, actual medical research
- the participants were regarded competent to make a decision regarding consent to 
medical research
- written in English
Studies were excluded if: 
- they were investigations of patients’ satisfaction with or subjective evaluations of the 
consent procedure
- they were hypothetical 
- the participants were healthy volunteers 
- the participants belonged to so-called vulnerable or  underrepresented groups of 
participants (psychiatric patients, geriatric patients, patients with dementia or 
Alzheimer’s disease, participants from developing countries or ethnic minorities, 
parents consenting for their children, or subjects in emergency situations)
4.2.1 Data extraction and analysis 
Relevant categories for analysis were identified and used by the first author and a co-author to 
develop a data extraction scheme. The starting point for the scheme was the research 
questions concerning definitions and measurements of understanding. The initial examination 
of the included studied comprised identifying which definitions and which assessment tools 
were used in the studies, in addition to study design.
During this first phase of data extraction, the category ”definition of understanding” was 
replaced, since most of the papers did not include such a definition. Instead, it was decided to 
extract information about the aim of the study, since this gave an opportunity to identify the 
terms the investigators used to refer to what they were measuring, and information about what 
kind of information the patients had received in advance (conversation, an ICD or both). 
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Furthermore, it was decided to extract details regarding the assessment tools, and thus this 
category was broken down into three categories (see the list below). 
The focus in the review was on methodology, and thus the results of the studies were not 
included in the data extraction scheme. The full-length papers were read (by the first author) 
and categorized according to the following headings and subheadings in the final data 
extraction scheme: 
I. Overall characterization of the study:
1. Design of the study (randomized or observational) 
2. Number of participants 
3. Materials collected (pre- and or post-test of understanding and when the test(s) 
was performed) 
II. What was measured? 
4. Whether the participants had received oral and/or written information before 
the test 
5. Aims of the study, including the words used for the phenomenon being tested, 
e.g. "understanding", "recall", "knowledge" etc.  
III. How was it measured?  
6. Assessment tool (i.e. questionnaire or interview, structured (MCQ, true/false, 
agree/disagree) or semi-structured) 
7. The number of measurements conducted 
8. Topics covered in the assessment tool  
The extracted data were presented in tabular format and thereafter synthesized into 
descriptions in order to make conclusions concerning the main research questions concerning 
the definition of understanding and how understanding has been measured in previous 
research (225).
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4.3 Paper III and IV: Document analyses 
Two document analyses are included in the thesis: one quantitative content and length 
analysis (paper III) and one qualitative linguistic analysis (paper IV). The sample of ICDs 
used in the first document analyses (paper III) was the corpus from which the subsample for 
the linguistic analysis in paper IV was selected.
4.3.1 Sample of ICDs
The sample in the quantitative document analysis of ICDs (paper III) consisted of 87 ICDs 
from oncological research approved by The Regional Ethical Committee in Central Norway 
(REC) in the period from 1987 to 2007. Approval for using the ICDs for analyses was given 
by the secretariat of REC and the documents were found by searching the committee's 
archives from its establishment in 1985. A total of 253 oncology studies were identified, and a 
subsample was drawn from these. The subsample consisted of ICDs from all the phase II and 
III studies of medical therapy for cancer patients evenly distributed throughout the years (a 
total of 41). From the remaining projects, ICDs from three studies per year (a total of 46) 
were selected randomly, yielding a total of 87. When less than three ICDs were available, all 
the documents from that year were included (from 1985 and 1986 no one was included). 
These studies included investigation/donation of biological material, testing of medical 
equipment, and observational studies of quality of life. 
The ICDs were scanned by using the Scansoft’s Omnipage SE® text recognition program into 
Microsoft Word® format. All the documents were proofread before analysis was performed 
to ensure that no words were misinterpreted by the scanning software.
The sample in the qualitative follow-up study (paper IV) consisted of the ten oldest and the 
ten newest ICDs from the original sample of 87 ICDs. Among the ten oldest, six were phase 
II/phase III clinical trials, and among the ten newest, five were phase II/phase III clinical 
trials.
4.3.2 Quantitative content analysis (paper III) 
Coding scheme 
The coding scheme for the quantitative content analysis of ICDs was a list of mandatory 
elements in ICDs. This list was based on the required content of consent information from the 
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Declaration of Helsinki (224), a three-page long guidance for authors developed by REC and a 
checklist of content elements developed by a working group nominated by the Ministry of 
Health and Social Affairs. A total of 45 content elements were derived from these sources. 
Thereafter, two other lists of essential content in ICDs were checked: The CIOMS’ 
International Ethical Guidelines for Biomedical Research Involving Human Subjects (40) and 
ICH Guideline for Good Clinical Practice (62). Two further elements were identified in these 
lists; yielding a total of 47 possibly mandatory content elements in ICDs (noting that not all 
elements are mandatory in all types of studies).
During the analysis, two investigators discussed the categories further when comparing scores 
for a selected number of ICDs. The comparison was made to ensure a reliable scoring. 
Agreement was found in 88% of the cases. For the rest of the cases, agreement was reached 
after a further discussion, which also contributed to refining the categories. 
One hypothesis behind the study was that there were some elements of content in ICDs that 
were of less relevance for patients. Based on this hypothesis, the content elements on the list 
were categorised in two overall categories: “basic components” providing information about 
fundamental medical and ethical aspects of the study and “formal components” giving 
information about formalities such as juridical aspects, financing, insurance and storage of 
data (17).
Word count and content analysis
A word count of the ICDs was performed by the Microsoft Word 2003 ® word count 
function.
The presence or absence of the 47 mandatory elements was identified in each of the ICDs and 
scored 0 (not present) or 1 (present), by the first author. In order to ensure reliability, a 
subsample of the documents (all ICDs from two of the periods) was re-scored by a co-author. 
The two investigators agreed in 88% of the cases, and the disagreement was discussed until an 
agreed-upon score was obtained. The rest of the ICDs were scored by one of the investigators 
on the basis of this process. 
The total scores were added up for each ICD, and also the scores for basic components and 
formal components respectively. Average number of elements and average number of words 
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were presented for three-years-periods in tabular format, and the development of number of 
elements and words were presented in scatter diagrams.  
4.3.3 Linguistic analysis of functional readability (paper IV) 
The Evaluative Linguistic Framework (ELF)
A linguistic framework, the Evaluative Linguistic Framework (ELF) (34), developed for 
studying text quality of written health information for patients, was chosen for the analysis of 
functional readability in paper IV. The framework was used to analyse the ICD’s readability, 
in other words, the ICD’s functionality in the specific situation it is used. The ELF was 
developed by Clerehan and colleagues to analyse the quality and possible shortcomings of 
drug information leaflets related to rheumatoid arthritis (32-34), by identifying those features 
that may or may not contribute to the fulfilment of writer and reader objectives (33). The ELF 
consists of nine items, and seven of these were used in the analysis. The two items excluded 
were lexical density and factual content. Lexical density was excluded, since – as far as we 
know – a number for average lexical density does not exist for the Norwegian written 
language, moreover this is a quantitative measure which is not considered relevant for the 
present analysis. Analysis of factual content was excluded since this kind of analysis demands 
specific medical and research expertise concerning the specific studies presented in the 
material. 
The ELF items, descriptions of them and corresponding assessment questions used to 
operationalize the framework are shown in Table 3 (34).
Table 3 The Evaluative Linguistic Framework for evaluating healthcare text  
Item Description Assessment 
Overall generic structure Series of themes in a document 
(e.g. “purpose of the trial”, “study 
procedures” or “participants’ 
rights”) 
What identifiable main topics are 
present? 
What is the order of the topics? 
The rhetorical functions The interactive functions 
performed for each theme (to 
inform, to instruct and to explain) 
What is linguistically being done? 
Is there clear guidance about what to do 
with the presented information? 
The writer-reader relationship Nature of the relationship between 
the writer and reader 
How are the intended audience and the 
writer addressed?  
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Is it clear who the writer and intended 
audience are? 
Is the relationship between writer and 
reader clear and consistent? 
Is the person who is expected to take 
responsibility for any actions clear? 
Metadiscourse Description of the purpose and/or 
structure of the text 
Is there a clear description of the purpose 
of the text? 
Headings Signposts in the text for the reader Are headings (main headings and 
subheadings) present? If present, are 
they appropriate? 
Technicality of the 
vocabulary 
The technicality of the expert 
terminology that is used 
What characterizes the expert 
terminology in the text? 
Are technical terms explained in lay 
terms? 
Visual aspects Aspects such as layout, font size, 
style, and use of visual material  
What is the length, layout, font size and 
the visual aspect of the document? 
Linguistic document analysis  
Using the ELF to analyse the ICDs comprised two main steps. Each of the seven items from 
the framework was analysed separately. The first step in the analysis was reading and re-
reading all the 20 ICDs, and extracting and marking relevant words, sentences or paragraphs 
directly in the electronic documents or on printed versions of the ICDs.
The second step was counting instances and placing the results into preliminary tables for 
each item in the ELF. Also, summaries of the identified textual characteristics were written. 
The preliminary tables and the summaries for the old and the new ICDs were compared. 
The analysis was mainly performed by the first author. When necessary, instances of 
uncertainty concerning the classification and interpretation of the textual elements were 
discussed by the first author and the second author until consensus was reached. 
 The analysis of generic structure was done by identifying and naming the main 
themes in the ICDs. A “theme” was defined according to the examples and findings 
presented in the studies by Clerehan and colleagues (32, 34). Themes are overall content 
units (for instance "information about study procedures" or "study background"). A 
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list of the identified themes was compiled for each ICD. The lists also included 
repetitions of themes and their placement within documents.  
 The analysis of rhetorical functions was done by investigating the linguistic and 
relational function regarding each identified theme (e.g. was the text informing or 
instructing?).  
 The analysis of the reader-writer-relationship was done in two steps. First, actors 
were identified as visible (explicit) or not visible (implicit); secondly, the ways of 
addressing and portraying the reader and writer were identified, and additional actors 
who were neither the reader nor the writer were also identified.  
 The analysis of technicality of language was conducted by identifying all words, 
phrases and sentences in which medical expert terminology or research expert 
terminology was used, and to determine whether the terminology was explained in lay 
terms.  
 The analysis of metadiscourse was performed by identifying descriptions of the ICDs' 
purpose and/or function and directions about how to read and interpret the text.
 The analysis of headings was done by identifying the main headings and subheadings 
and determining the headings' appropriateness by comparing the topic in the headings 
with the subsequent content.
 The final item, visual aspects, was analysed by counting the number of pages and 
identifying the graphical elements in the ICDs.  
Finally, the readability of the identified and categorised textual characteristics was interpreted 
as “more readable” or “less readable” based on theoretical premises of reading comprehension   
that are the basis of the ELF.
4.4 Ethics 
The POP trial (paper I) was approved by the Regional Committee for Medical Research 
Ethics, Health Region Central Norway, and the participants in paper I gave written informed 
consent (the signed consent forms have been destroyed in compliance with the instructions 
from the privacy ombudsman for research). The document analysis (paper III and IV) did not 
need an approval of the ethical committee. The committee secretariat gave the permission to 
use the ICDs from the archive.  
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5 Summary of papers
Paper I
Lung cancer patients’ perceptions of informed consent documents 
The participants in the study were patients eligible for a trial of palliative chemotherapy for 
lung cancer (N = 22). They were randomized to receive either a original ICD or a shortened 
version. Semi-structured interviews were conducted after the patients had read the ICDs. The 
interviews were based on a broad interview-guide with questions concerning the patients’ 
perception of the content and language in the ICDs. A qualitative content analysis was 
performed, including both deductive and inductive categories.
Overall, the analysis showed few differences between the patients who read the original ICD 
and those who read the modified version with respect to their subjective assessment of the 
amount of information, whether some of the content was perceived as redundant, or whether 
they would have preferred some additional information. Most of the participants seemed to 
have problems with talking extensively about their own assessment of the content in the ICDs 
and to evaluate what kind of information they wanted or not. They mostly gave short answers, 
for instance that the text was all right, easily understood, and not complicated to read, giving 
the impression that they were satisfied with the document. Seven patients said they wanted 
additional information. Three of these specified this by referring to more information about 
the treatment and side effects. Over half of the patients said that the most important 
information was to know that they are contributing to science and helping future patients.
When asked specifically about their opinion of the research formalities in the ICDs, half of 
the patients stated that reading about the research formalities were unnecessary, while seven 
patients thought it was relevant or interesting information (three did not answer).  
One of the inductive categories in the study is made up by questions the participants posed to 
the interviewer during the interviews. Fourteen of the patients asked quite a few questions to 
the interviewer, showing that they took initiatives, they contributed to the dialogue and they 
were active in trying to get the information they wanted. These questions were an indication 
of which aspects that the patients would like to know more about (i.e. what we were looking 
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for by asking them questions about what further information they would have wanted). The 
main topic in these questions was treatment procedures such as: “at which hospital will I 
receive my treatment”, “who will perform the blood tests”, “who can I call if something 
happens” and “will I lose my hair?”.  
Two other inductive categories were identified during the analysis, which might contribute to 
the total picture of the informed consent process: The unfamiliar situation and the trust in 
health care professionals. Being seriously ill and being at a hospital was unfamiliar for many 
of the patients, feelings that might influence their ability to understand written information. 
Eight patients expressed their complete confidence in the physician and the hospital, and this 
trust was related to their lack of interest in research formalities. It was not crucial to remember 
every detail in the ICD as long as they trusted the physician. Even though most of the patients 
gave the impression of understanding that the main purpose of is to contribute to generate 
new knowledge that would benefit future patients, they also felt confident that the physician 
acted in the patient’s best interest.  
This study showed that the patients were most interested in the practical information about the 
study procedures and the information that was most directly related to themselves and their 
situation. This indicates that the patients’ information preferences do not correspond to the 
ethical guidelines prescribing a wide range of research-related content in ICDs.
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Paper II 
The Understanding of Informed Consent Information – Definitions and 
Measurements in Empirical Studies 
Eleven hundred and nine titles, abstracts, and publication types were screened for relevant 
studies, of which 306 were duplicates. Sixty full-text articles were retrieved and read. 31 of 
these met the inclusion criteria, while the hand search yielded four additional publications. 
Thus, 35 papers met the inclusion criteria. Since two of these reported the same data 
collection, the number of reviewed studies, was 34. Eleven of the studies were randomized, 
while 23 were observational studies. The number of subjects in the studies ranged from 8 to 
1789, with a median of 62 and a mean of 146. In 27 of the studies, understanding was 
measured once (in a post-test), while in seven studies understanding was measured more than 
once.
Several different terms were assigned to the variable to be measured, for instance 
“understanding,” “comprehension,” “recall”, “knowledge”, “perception”, “retention,” 
“awareness”, and “recognition”.  Four to six different terms were used within the same paper 
in several occasions. However, a definition of what these terms implied or the distinctions 
between them was seldom given.
Only four of the studies included some sort of definition of and/or distinction between terms, 
for instance a distinction between memory and comprehension. In these studies, 
comprehension was seen as the most relevant variable to measure, since the authors found it 
less relevant to investigate what the patient remembers a certain period after having read the 
ICDs. Comprehension is vaguely referred to as “what is known at the time the consent was 
obtained”.
Exactly what kind of information the measurement was related to varied to a certain degree 
between the studies. Most common was to investigate the subjects’ understanding of research 
in general or related to the specific study. Two studies measured the subjects’ understanding 
of a specific aspect of the information, while three studies specified a wide range of 
information aspects the test addressed.  
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Most of the studies used questionnaires or structured interviews for measuring the subjects’ 
understanding. The questionnaires were in most cases developed specifically for each study. 
The questionnaires differed substantially with regard to number of items, which topics were 
covered, and time of measurement. The number of items varied from 2 to 23 (median 9 ½). 
The content of the items were divided into two main categories: (1) Generic questions
(concerned research in general, for instance what is the reason for doing clinical research) and 
(2) Trial-specific questions. The latter category included questions either specifically related 
to research aspects (“all women in the study will get the same cancer-fighting drugs” 
true/false) or not (“which of the following side effects could be caused by the drug you are 
taking?”). The time of measurement varied from one hour after consent interview to two years 
after the closure of the study.
In 15 of the studies, no description of the development of the measurement tool was given. 
Only two studies described the entire development and testing of the questionnaire. The rest 
to a varying degree described the rationale for the items, for instance that the items were 
based on guidelines for consent information or on the information the subjects actually had 
received.
The findings of this review confirm a lack of definition of the term “understanding” and large 
degree of variation in regard to how it was measured. This variation hinders comparisons of 
findings and thus the improvement of  ICDs based upon empirical findings. In order to find 
out what makes ICDs difficult to understand, a crucial initial step is to answer the question 
“What does is imply to understand an ICD?”. 
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Paper III 
The length of consent documents in oncological trials is doubled in twenty 
years 
The material in this study consisted of 87 ICDs from oncological trials approved by the 
Regional Committee for Medical and Health Research Ethics (REC) in the central region of 
Norway between 1987 and 2007. Based on the guidelines for content in ICDs, a list of 47 
mandatory content components was derived. Seventeen of these were categorized as “basic 
components” (i.e. fundamental medical and ethical aspects) and 30 were categorized as 
“formal components” (i.e. juridical and financial matters, insurance and data safety and 
storage). The analysis was performed by counting the number of words in each ICD and the 
presence of each content element were registered for all ICDs. 
The mean length of the ICDs increased from 338 (range 276–464) words in 1987–1990 to 
1087 words (range 399–2345) in 2005–2007. The number of words in the entire period 
ranged from 165 to 2345. 
The mean number of components increased from nine in the 1987–1989 period to 25 in 2005–
2007. The presence of basic components increased steadily from seven in 1987–1989 to 14 in 
2005–2007 while the presence of formal components increased substantially from two to 11. 
The increased length of the ICDs is mainly explained by an increased complexity of the 
documents and especially more information about research formalities.  
The number of words describing basic elements increased from a mean of 302 (range 184–
464) in 1987–1989 to a mean of 833 (range 320–1807) in the 2005–2007 period. The number 
of words addressing the formalities increased even more with a seven doubling from a mean 
of 35 words (range 0–92) in 1987–1989 to a mean of 254 words (26–538) in the 2005–2007 
period.
When writing ICDs according to the lists of mandatory information, the documents become 
long and contain a vast amount of information. Thus, the content regulations of ICDs might 
just as well hamper the patient’s understanding as result in well-informed trial participants.  
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Paper IV 
Readability of informed consent documents, 1987-2007 – a linguistic approach 
The ICDs’ characteristics were identified by use of a linguistic framework previously 
developed for investigating text quality in written health care information for patients. The 
items included in the analysis were: Present themes, the order of the themes, the acts 
performed by language (to inform, to explain, to instruct), the actors present, the interaction 
between the actors, the use of expert terminology, the use of metainformation (i.e. 
information about the text) and the use of visual aspects. The broad characteristics of the 
ICDs were interpreted according to theoretical premises of reading comprehension that are the 
basis of the framework. 
Several aspects were found to contribute to readable ICDs. First, readable ICDs place 
essential information in the beginning of the text, both in order to highlight the main topics 
and to create a frame of reference which would help the reader to understand the rest of the 
document in an appropriate manner. Essential information would be the request to participate 
in research, that the reader is supposed to make a decision, and that his choice is completely 
voluntary. Second, readable ICDs maintain focus on research implications throughout the 
document. This implies to also present information about diagnosis and/or treatment as 
related to research. Third, readable ICDs give a clear picture of the reader and what he/she is 
supposed to do with the information (use it as a basis for decision-making) and a clear picture 
of the writer and other actors in the text, and their roles in the research procedures. Forth, 
readable ICDs use expert terminology in order to be precise, and explain expert terminology 
in lay terms when necessary.  
Finally, readable ICDs include explicit assisting formulations such as instructions to the 
reader about how to consent, metainformation that presents the main goal and topics, 
subheadings which help the reader navigate in the document, and visual aspects to emphasize 
key elements. 
The comparison of readability in old and new ICDs showed that the new documents were not 
clearly more readable or less readable than the old ones. Some textual characteristics would 
reduce readability while others would increase readability. On the one hand, readability in the 
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new ICDs was reduced due to more information, more details, and more complex 
presentations of actors and actions. On the other hand, the new ICDs were more research 
oriented than the old ones both in the beginning and throughout the text, the new ICDs 
included instructions to the reader about what to do if he wanted to consent and detailed 
contact information, aspects that increase the readability. The old ICDs were only one page 
long. The old ICDs scored higher on presentation of clear interaction between the actors in the 
document, for instance due to less additional actors. These aspects might increase readability. 
However, the old ICDs contained a relatively large proportion of information about the 
reader’s diagnosis and treatment, and were thus less oriented towards research, which might 
reduce the goal-oriented readability.  
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6 Discussion 
The main findings in this thesis were that:  
- Patients reading ICDs mostly were concerned with practical information about their 
own treatment 
- There is no consensus concerning what it means to “understand the information in an 
ICD” and how understanding should be measured.  
- ICDs for oncological trials have become longer during the past decades, and the 
number of topics included has increased 
- Despite increased length and amount of information, the textual organization of newer 
ICDs makes them more functional 
To give an informed consent to research is a process that consists of more steps than reading a 
document and signing it. Particularly the dialogue between the physician and the patient is of 
great importance. There are reasons to believe that oral information about a medical study is 
at least as important as the written information for many patients, and perhaps also for 
physicians. A face-to-face consultation gives the patient the opportunity to ask questions, and 
the physician the opportunity to respond to the questions, to repeat information, and to assess 
immediately if the patient has understood (203).
A study of reading and signing various legal documents showed that nearly four out of ten 
participants had signed legal documents without reading them (216). Reasons mentioned for not 
reading the documents were for instance trust, that the contents had already been explained by 
someone, or that the document was too difficult to read. On the other hand, the oral 
information is not standardized, there are possibly large variations between consultations, and 
there is also a possibility for a certain level of manipulation. Written information ensures that 
every eligible participant receives the same information, and the document can be kept as 
documentation of essential information that is always available for the participants (184). The 
oral information is not the scope of this thesis.
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6.1 Discussion of main findings 
6.1.1 Patients’ assessment of ICD contents (paper I) 
Information preferences vs. content regulations 
The results of the POP trial (paper I) showed that the patients were mostly concerned with 
information about the practical aspects of their treatment, and less interested in research 
formalities about the trial for which they were eligible. It seemed difficult for the informants 
to evaluate the documents extensively, and several of them expressed a high level of trust in 
the physicians. These results are in accordance with the results in the study by Karen Cox 
who investigated cancer patients’ perceptions of the informed consent process and their 
descriptions of the decision-making process. The patients in Cox' study seemed to want the 
kind of information that enabled them to know what is going to happen next, in order to have 
some control over the situation (43).
The POP trial and the Cox study were both oriented towards the relationship between the 
content regulations of the ICDs and the reader’s information preferences in the consent 
process. Cox pointed to the challenge of providing information that “ensure that the legal 
requirements of informed consent are fulfilled on the one hand, and helping patients get the 
information they want and understand in order to make a genuinely voluntary and informed 
decision on the other” (43). The patients' preferences in the POP trial indicated that their 
information preferences were not in accordance with the content regulations concerning 
medical research, since many of them were mostly concerned with information regarding 
disease and treatment.  
According to David Casarett and colleagues there are at least two challenges regarding how to 
inform the patient based on the regulations of content (28). The first is a qualitative challenge: 
Of all the possible information included in the broad categories of mandatory content, what 
does the patient want? The other challenge is a quantitative one: How much information does 
the patient expect? The starting point for the Casarett-study, the POP trial, and also for a 
recent similar study of patients’ information needs (124) was the patients’ information 
preferences regarding the mandatory information. Since the qualitative content analysis in the 
POP trial also included inductive categories, it was possible to identify other information 
preferences than those related to mandatory information. Overall, the patients in the POP trial 
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seemed to be more interested in information not related to the mandatory research information 
than in mandatory formalities. These findings yield a third challenge in the consent process: 
How to ensure that the patients understand that the information in the consent consultations 
and ICDs are about research and not about treatment per se? 
It is important to point out that to investigate the patients' information preferences in the 
consent process does not imply that the ICDs should contain only the information the patients 
want, because the patients are not aware of all the contents necessary to convey for enabling 
patients to make a decision about participating in research. It is necessary to follow guidelines 
written by experts (medical, juridical, and ethical experts). Still, it is of relevance to find out 
which content the patients find to be of relevance in order to convey and organise the 
information in such a manner that it as far as possible meets both the patients’ needs and the 
formal requirements.  
It is of course not surprising that cancer patients prefer information about their own diagnosis 
and prognosis. In the consent process, however, it is crucial to clarify that the information first 
and foremost concerns participating in a medical study, and that participating in a study 
differs from getting treatment outside of the study. The patient should get all the information 
he wants about his own situation, but he/she has to relate it to the research implications if the 
aim is to obtain a valid decision concerning research participation. 
Contextual factors of relevance in the consent situation 
The POP trial revealed contextual factors of relevance for how the patients in the POP trial 
related to the ICD. They were in an unfamiliar situation, they were severely ill and they 
trusted their physician, some of which might diminish the capacity to comprehend trial 
information. In a previous study it was shown that patients trusted the physician, the hospital 
and the research enterprise as a whole, and consequently, the details in the consent form were 
not particularly relevant for them in their decision-making process (118). Findings concerning 
contextual factors confirm that investigating actual research participants in actual consent 
processes is essential for understanding how the information is perceived. As a consequence, 
contextual factors should be taken into consideration when writing ICDs, when reviewing 
ICDs and when investigating the effects of different ways of informing patients.  
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6.1.2 Testing understanding of trial information (Paper II) 
A review of methodology gives an overview of potential sources of strengths and weaknesses 
in a specific field of research. In the field of informed consent, the problems of vague or 
lacking definitions of understanding and no standardized way of measuring it, had been 
referred to by previous review authors (see section 2.3.1), but had not been studied 
systematically prior to the publication of paper II. The findings in this paper showed that 
previous concerns regarding the heterogeneity and shortcomings in the field certainly were 
correct. As Appelbaum described it in his editorial accompanying the publication of paper II, 
the measurement of understanding has been “a conceptual and methodological chaos” (9).
Three main aspects were found to constitute the chaos: First, the definition of the term 
"understanding" (or whatever term was used) was absent in 30 of the 34 included studies. 
Terms such as understanding, comprehension, knowledge, recall, and retention were used 
interchangeably. By looking at the items in some of the assessment tools, it seems more 
accurate to say that recall or memory was measured, not understanding: 
- What special tests will be done while you are in the study? Check only the correct 
items (Electrocardiogram / X-ray of the brain / Blood tests / Radioactive liver scan) (18)
- You will be required to return to the clinic at intervals of: (one week / two days /  one 
month / two months / two weeks) (152)
- The phase I trial is an investigational treatment (agree / disagree) (111)
- Can I be part of the trial if I am pregnant? (52)
- The drugs used in the trial are completely safe (agree / disagree /don’t know) (46)
The reason for recall not being sufficient for giving a truly informed consent is related to the 
ethical foundation of the informed consent, and not the guidelines regulation the content, 
which mostly lists the essential content. An ethically valid informed consent requires that 
participants truly understand and freely decide to participate (70). As mentioned in 2.1.1, to act 
autonomously is not just merely to do what one wants, but to do it based on thought and 
reasoning (77), and that implies to understand the implications of the options one have in the 
consent process – to consent or to refuse – not only remember factual information about the 
study procedures (see recommendations for items below).  
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While most of the included studies in paper II did not include definitions or reflections upon 
what understanding is  or what recall, retention or knowledge is  a few of the studies 
addressed that there are differences between remembering  and understanding (66, 67, 94, 128, 166).
Hassar and Weintraub stated already in the 1970s that “Some subjects remembered, but 
misunderstood what they had been told”, indicating that to remember is not the same as to
understand (94). And as shown in section 2.3.1, Featherstone and Donovan (67) found in their 
interview study that even if their respondents showed good recall of randomization, they still 
did not understand the principle of randomization completely (i.e. that recall and 
understanding is not the same, and that recall does not necessarily lead to understanding): 
“The case studies of each man showed that all were involved in what was, essentially, a 
struggle to make sense of their participation”. Featherstone and Donovan’s findings suggest 
that to understand could be defined as “to make sense of”, and that to measure recall or 
memory might not be sufficient to find out if the participants have made sense of the 
information to a sufficient degree to be capable to give informed consent (66, 67).
Related to the question of what to measure, is the question of when to measure. The studies 
included in paper II, showed no consensus concerning the appropriate time between the 
presentation of information and the assessment. In some of the studies, the assessment took 
place months or even years after the information was disclosed. (80, 98, 99). However, the 
information in the consent process is intended to be used to facilitate decision-making in a 
specific situation, and for being able to give an informed consent to research, there is simply 
no need for a patient to remember the information for a long period of time afterwards  
Secondly, the included studies showed that there is no consensus about what information 
must be understood in order to be enabled to make a truly informed consent (9). One might for 
instance question whether these three questions actually constitute an assessment tool for 
assessing the ”basic knowledge about the trial” (85): (1) the purpose of the study, (2) the name 
of the study medication and, (3) the main side effect from the medication (85). The purpose of 
the study would be a basic aspect of importance to recognize for the eligible subjects, while 
the name of the study drug seems of less importance. To understand what it implies to take 
part in a medical study are not dependent on whether the participant remembers the word 
gemfibrozil.
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Thirdly, the included studies in the review showed a lack of standardized assessment tools 
for measuring understanding. The assessment tools were for the most part developed for each 
particular study, something which resulted in a large degree of variation between the 
assessment tools. The assessment tools consisted of a variable number or items (range 2-23 
(172)) and the items covered different contents; some items were related to research in general 
and some to the specific trial. A systematic overview over the contents of the assessment tools 
have never been presented prior to paper II. The development of a standardized tool should be 
based on a common definition of understanding and a consensus about what information that 
needs to be understood (see suggestions below). 
In his editorial, Appelbaum pointed out that the methodologic diversity in the field is not the 
same as claiming that the individual studies lack value in themselves. Some of the studies of 
participants’ understanding are of high quality (9), it is the comparison of them that is 
problematic, since comparisons will be of limited value if one does not really know what is 
measured, and if the methods used to assess understanding are very different (9, 172).
A few questionnaires for testing understanding have been developed and validated meant for 
further use in other studies (110, 116, 146). Of these, the Quality of Informed Consent (QuIC) is 
the only one that has been used by quite a few other investigators (11, 12, 176), and it has been 
translated to Finnish (99), French (159), and Korean (124), indicating that in the last five years, a 
certain standardization of the assessment have taken place. However, also during the last five 
years, investigators have continued to develop new questionnaires for measuring patients' 
understanding. Three such examples are described as follows: “a 21-item, true/false 
"Assessment of Understanding" (AoU)” (59), “a comprehension questionnaire which was 
designed by the study team” (21), and "In an effort to ensure that participants adequately 
understood study information, investigators developed a 20 item true/false comprehension 
quiz" (29). The problem remains that investigators mix up the term understanding with other 
terms such as knowledge and recall, as exemplified in the following comments: 
“understanding, including self-perceived understanding and retained knowledge” (138) and 
“questions were primarily focused on assessing the respondent's recall of key elements of the 
informed consent, which were understanding the fact that his/her child was participating in a 
research study […]” (173).
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How to operationalize understanding and develop measurements? 
To measure understanding of the information in ICDs, there is a need to clarify the major aim 
of the information. The guidelines for medical research do seldom specify the overall aim of 
the information. However, in chapter 8 of ICH Good Clinical Practice (62) it is stated the 
purpose of the “informed consent form” is “to document the informed consent”, and that the 
purpose of “any other written information given to trial subject” is to “document that subjects 
will be given appropriate written information (content and wording) to support their ability to 
give fully informed consent”. It is plausible that “any other written information” is referring 
to the actual description of the study (the ICD). In other words, the aim of the ICD is to 
facilitate the research participant’s decision-making.  
How could that aim be achieved? There is a need to help the reader to understand what 
research is and the implications of being a research participant. According to Paul Appelbaum 
and colleagues, in their presentation of the so-called “therapeutic misconception” (TM) (7), it 
is crucial for the research participants to understand that the overall aim of research differs 
from the aim of individual treatment. The aim of research is to generate knowledge which 
might benefit future patients, and TM might occur when the research participants are not able 
to distinguish the dual role of their caretaker, being both a physician and an investigator or the 
implications of this. The TM occurs because the participant has a more or less “therapeutic 
mind-set towards the study” and thus interpret what they read and experience “as related to 
their individual needs” (7). Based on this, it is an aim of the ICDs to facilitate that the reader 
gets a “research mind-set”. This mind-set would help him to interpret the information in the 
appropriate manner and help him understanding the differences between treatment and 
research.
Based on the abovementioned definition of understanding, an instrument based on retelling in 
own words might be an approach for measuring understanding, as for instance in the 
interview studies of Featherstone and Donovan (66, 67).  However, the results of such methods 
might also be difficult to compare, since there would be a high extent of researcher’s 
interpretation in the analyses, and the sample size would be small.  
In order to develop quantitative instruments measuring the ICD reader’s understanding, there 
is a need to include items related to research in general, the overall aims of research, why 
patients are included in research, the specific study he is asked to participate in, and the 
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implications of consenting or refusing. One example of a questionnaire including some of 
these items is the one developed by Strevel and colleagues (192) who initially asked the 
participants whether they had heard of “clinical trials” and “phase I clinical trials” and about 
what ”a treatment clinical trial” is and what is the goal of a phase I clinical trial. These 
questions address the participant’s background knowledge and the “research mind-set”.  
A questionnaire developed for measuring clinical trial participants comprehension of ICDs in 
India is another example of an instrument clearly directed towards the overall aims of 
research and towards the participant’s background knowledge (21, 178). The questionnaire is 
divided into four main parts, called Background of the study, Study design, Participants’ 
rights and Miscellaneous. The firsts questions in the questionnaire are: “Do you understand 
that you are being asked to participate in research?”, “Why is this research being done?”, “For 
whom will this information be useful?” and “Why are you being invited to participate in the 
research” – i.e. basic questions about the goal of performing the study and of the participant’s 
role in it.  
6.1.3 ICDs over time: Both more complex and more functional (paper III and IV) 
The main results of the analysis in paper III were that the ICDs for cancer trials in Norway 
had become considerably longer from 1985 to 2007, that they consisted of an increasingly 
larger number of content elements, especially regarding research formalities (paper III), and 
that longer documents not necessarily were less readable than the shorter (paper IV).  
Continuously increasing length of ICDs 
The results in paper III concerning increased length of ICDs confirmed findings from 
previous studies of the development of ICD length (10, 12, 129) and has also been confirmed later 
(4). Increased length of ICDs have been considered to lead to documents that are more difficult 
to understand (4, 12, 60, 134, 179).
While previous studies have studied length and readability (12, 179), paper III related increased 
length to increased number of content elements in the ICDs. Not only the length per se, but 
also a large amount of topics might influence the reader’s comprehension process.
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Recent studies, from all over the world, have also examined the presence of mandatory 
content in ICDs (3, 136, 157). The aim of these studies was to find out whether the ICDs contain 
the information they should, while the aim of paper III was more descriptive: To investigate 
the amount of information in the ICDs, whether the amount had increased, and what kind of 
contents were added during the last years. The increasing number of content elements 
identified in the ICDs were in accordance with the described development of more extensive 
regulations of information to medical research participants during the period of investigation 
(see section 2.1.2), i.e. the more extensive regulations, the more extensive ICDs. The 
prescription of content are developed in the patients’ best interest, and the writers of ICDs 
obviously do what they are told to do, resulting in long ICDs saturated with information. 
Baker and Taub addressed the paradox related to this development already in 1983, before the 
large increase of detailed content regulations took place in the 1990s: 
“Efforts to protect the rights of research subjects through federal regulations have 
resulted in presentation of appropriate information, but little progress has been made 
in ensuring that the information is comprehensible, understood, and used” (10).
When the challenge of long ICDs with more and more content still is a reality, one might ask 
whether the next step would be to modify the regulations in a new manner. A modification of 
regulations could imply both a reduction of the number of mandatory content elements and, 
and not least, additional instructions about how to present the information, i.e. instructions 
about headings, wording, order of content, how to emphasize information (and what 
information should be emphasized) etc.   
Longer ICDs, but not necessarily less readable 
That the included ICDs represented a long period of time and that the results from papers III 
and IV were compared made it possible to reach a nuanced picture of ICDs which is rather 
unique in the field of informed consent research. The findings in paper IV showed that even 
though the ICDs had become longer during the 20-year period, they are not necessarily less 
readable, in the sense of being functional for their readers. Also according to a recent study by 
Stunkel and colleagues, there were no correlation between length of the ICD and patient 
comprehension of study information (193).  This indicates clearly that brevity per se is not a 
sufficient factor for readable ICDs. Other textual aspects than length and scores on readability 
formulas contribute to more functional information. The newer ICDs in paper IV were for 
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instance more oriented towards the topic of research than old ones, and included a clearer 
request about participation and clearer instructions about what to do if one wants to consent.
Albala and colleagues have later investigated the length and one content element, description 
of risk, in ICDs in a study with a longitudinal design (4). The results showed two trends similar 
to the results in paper IV. Despite an increased length of ICDs during the 25-year-period, the 
descriptions of risks became less discrepant, suggesting that the writers and reviewers of ICDs 
are more concerned with accuracy and completeness of the information. Albala et al pointed 
to the paradox of a greater level of accuracy leading to increased length (4), which, as in paper 
IV, indicates that longer ICDs are not necessarily less readable than short ones since they 
might be more precise.   
Linguistic analyses of ICDs are rare, but linguistic modifications of ICDs have been done in 
randomized studies comparing a modified document with the standard document. For 
instance, Bjorn and colleagues revised the language, style and layout of two ICDs for medical 
procedure (not medical research), by breaking down the text into smaller segments, adding 
subheadings dividing long sentences into smaller, and replacing professional language with 
lay language (22). This revision was based on linguistic analysis of ten ICDs, and “a number of 
problems were identified”. These problems were, however, not presented in their paper, 
neither their analytic framework (22), and thus it is impossible to address these problems in 
future attempts of modifying ICDs. On the contrary, a pre-developed, broad linguistic 
framework as ELF (paper IV) made it possible to specify possible problems of ICDs, for 
instance: 
- not suitable thematic focus (when research were not thematically highlighted)  
- not functional introductions (when the main message of the ICDs were not introduced 
in the beginning) 
- limited use of explanations of expert vocabulary 
- unclear presentations of the actors and what they were supposed to do 
- inappropriate headings (when the headings does not cover the content in the body 
text) 
- no use of metainformation 
The findings in paper IV is therefore of value for specific recommendations for how to write 
and organize ICDs.
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Jefford and Moore summarizes a part of the field of research of ICDs by referring to the 
language modifications, such as modification of content, writing style, format, or length of 
ICDs, that have had limited effect on the readers' understanding (112). Still, they do believe that 
"attention must continue to be paid to the language of consent forms". The refer to terms such 
as "simplification" of ICDs and "simplified" language when they present what have been done 
in previous research or recommendations for what should be done in future writing of ICDs. 
However, the solution for writing understandable ICDs is perhaps not "a simple language" 
comprised of shorter sentences, shorter words and lay terms only, but, as the results in paper 
IV indicates, a better organized information with a clearer focus on the main message of the 
ICD. Furthermore, the specific problem areas of ICDs, as identified in paper IV, makes it 
relevant to suggest that guidelines for information to eligible research participants should 
comprise instructions about how to inform, not only what to say, as is the case in many of the 
current guidelines (see section 2.1.2). 
6.2 Methodological considerations 
Three of the studies in this thesis are qualitative studies (papers I, II and IV), thus, the main 
methodological considerations were how to achieve validity and reliability in these qualitative 
studies. It was important to recognize the differences between qualitative and quantitative 
research in the way reliability and validity are defined. 
6.2.1 Research quality assessment: Validity and reliability  
The rigour and trustworthiness of research are demonstrated by the validity and reliability of 
the procedures (168). The strategies for establishing validity and reliability differs in qualitative 
and quantitative research (212). Since the 1980s, there has been an on-going extensive debate 
concerning whether the terms reliability and validity are useful in qualitative research, 
whether other terms should be used instead, and, in that case, which terms, or whether the 
terms should be treated as a whole under a term such as trustworthiness (148). This debate is 
out of the scope of this thesis (see for instance (36, 91, 148)). In this thesis, the terms reliability 
and validity are used in accordance with those who have argued that the terms reliability and 
validity are appropriate for all kinds of research, since the aim is to obtain rigour independent 
of research questions and methods (see for instance Janice Morse and colleagues (148)).) 
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Validity in qualitative research concerns similar aspects of research as in quantitative 
research: To ensure that one measures what one purports to measure (65) so that the study 
produces valid results. This has been referred to as “internal validity”, while “external 
validity” refers to in what degree the results are generalizable to a more general set of 
circumstances than the specific population under investigation (202). In this thesis, the term 
“validity” is used for the former and “generalizability” or “transferability” for the latter.  
In quantitative research, validity is closely related to the study design and to the measurement 
methods, and strategies such as randomization and blinding are used prevent biased results. 
Validity is also ensured by estimating the sample size needed for enabling generalizable 
results (191). In qualitative research, validity to a larger degree concerns the entire research 
process. There are some overall, key elements of a valid qualitative research process: First, it 
is important to select an appropriate method for investigating the research questions and to 
apply the method in a coherent and rigorous way (36, 148).
Secondly, regarding sampling strategies, one might ensure validity by including the 
participants that best represents what the investigator is interested in and who have knowledge 
of the research topic (148) or by choosing participants with various experiences to get a broad 
spectre of perspectives on the research topic (84). Thirdly, the researcher in qualitative studies 
is not a neutral part in the investigation, and it is not an aim to remove every aspect of 
investigator biases. However, the investigator needs to be keenly aware of how he/she 
influences the data collection, analysis and results (122, 140).
Other strategies for validation of qualitative studies: 
- Triangulation: to use multiple research methods, for instance collecting different kinds 
of data, combining qualitative and quantitative methods or collaboration of analysis 
between the investigators (89, 180, 199). The aim of triangulation is to increase the 
investigators’ ability to interpret the findings (199), and is most often not regarded as a 
test of validity (140).
- Iteration: to move back and forth between data and analysis have been considered to 
be the essence of attaining reliability and validity in qualitative studies (148).
- Informant validation or member checking: to compare the researcher’s account with 
the informant (140). This procedure is not a part of this thesis, since the researcher’s 
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account are regarded as interpretations of entire data sets, and not necessarily 
something patients or ICDs writers recognize as “correct”.
Generalizability is also relevant for qualitative studies. Even if the aim of qualitative 
research is not to generate knowledge that could be generalized to a larger population (135), the 
results should have a certain degree of transferability beyond the investigated situation (133).
To facilitate transferability, the investigator should give a clear description of the situation of 
data collection, the selection and characteristics of the participants and of the analytic process 
(84).
Reliability has been argued to be less suitable for qualitative research than for quantitative 
research (81), since the term is related to accurate representations of the natural world (36) and 
reproducibility – aspects that are not in accordance with the aims and procedures of most 
qualitative research. The aim is to broaden the understanding of the investigated phenomenon 
(125)). Thus, reliability in the qualitative paradigm does not mean to obtain exactly the same 
result time after time, but to achieve consistent results (36, 125). However, this is not to say that 
the aim of qualitative analysis is a total consensus of how to interpret the data. Reliability can 
be achieved, for instance, by choosing analytic procedures that are well-known and validated 
(36). The procedures should be performed and described in detail.  
Inter-rater reliability or co-researcher dialogue has been argued to enhance reliability of 
qualitative analysis, i.e. dialogues between two or more of the involved investigators to ensure 
consensus in coding, to identify topics or patterns that one investigator may have missed, or 
for completing the interpretations (47, 58, 84). The co-researcher dialogue is not supposed to 
remove the level of subjective interpretations in the analytic process, because this is exactly 
what characterizes qualitative research: the extensive interaction between the researcher and 
the data. The researcher’s “in-depth familiarity will undoubtedly affect the subsequent 
interpretation” (47). In developing a data extraction scheme, the categories must be as precise 
and replicable as possible (182) to ensure reliability, and co-researcher dialogue may be used. 
Reliability is also enhanced by giving clear, transparent descriptions of the process of data 
collection and analysis (122, 140).
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6.2.2 Sample representativeness 
This thesis is concerned with the ICDs related to cancer research and thus cancer patients. 
Cancer patients are a heterogeneous group with large variations in age, gender and education 
with different diseases treated quite differently and with considerable variation in expected 
outcome. Also comorbities vary between cancer patients and effect upon the health state of 
cancer patients. 
Patients (paper I) 
It is considered a strength that the sample in paper I consisted of patients who were actually 
eligible for a clinical trial and who were interviewed about an authentic ICD. An appropriate 
sample, consisting of participants who best represent or have knowledge of the research topic 
is one of several verification strategies that ensure reliability and validity in qualitative studies 
(148). Although there are several studies of hypothetical scenarios in the field of informed 
consent, including patients or healthy volunteers being informed about hypothetical trials (55, 
68, 83, 119, 169, 188, 207), such studies are less likely to be representative and valid for cancer 
patients.  
The study cohort in the POP trial is not necessarily representative for a general cancer patient 
population, due to several factors: 
- The sample size was small 
- The patients had advanced, incurable/inoperable lung cancer 
- The patients were diagnosed at one hospital only
- The patients’ performance status was good enough for being referred to 
chemotherapy, indicating that they were more fit than many other patients advanced 
disease
- The patients had consented to the POP trial, i.e. consented to take part in an interview 
During the 10 month inclusion period for the POP study, it was estimated that approximately 
70 patients were diagnosed with advanced NSCLC in the county in which the POP study 
were conducted (24)3, suggesting that less than 2/3 of all potentially eligible patients were 
3 Data from the Cancer Registry of Norway has been used. The interpretation and reporting of these data are the 
sole responsibility of the authors, and no endorsement by the Cancer Registry of Norway is intended nor should 
be inferred.
79
asked to participate in the trial. The participants in the POP trial are considered to be 
representative for this selected group of lung cancer patients, i.e. the results represents how 
these patients assess the content of an ICD for an actual clinical trial.  
However, background variables of gender, age and level of education reflect some general 
characteristics of lung cancer patients.
- Gender: There was a slight preponderance of men among the POP participants 
(54.5%), as there was similar preponderance of men among new cases of lung cancer 
patients in 2006 (one of the years in the inclusion period) (59 %) (24).
- Age: Median age of the POP participants were 69 years, which is close to median age 
for lung cancer debut (median 72 years (57)).  
- Education: The POP trial participants’ level of education was lower than in the 
general population (189), which is common for lung cancer patients. In Northern Europe 
and Germany, there is a correlation between low education level and lung cancer in 
large mediated through smoking (145).
The sample might to some extent also be regarded as representative for a general lung cancer 
population. This means that the findings in the study might be a basis for what to bear in mind 
when writing/reviewing an ICD for severely ill, low educated lung cancer patients who have 
smoked their entire adult life.
Sampling strategy 
The POP trial was a randomized, add-on study of an RCT of chemotherapy for advanced non-
small cell lung cancer (the PEG trial). The sampling strategy of the POP trial followed the 
same principles as in the parent RCT, i.e. a sampling strategy for quantitative studies in which 
the participants were selected from a larger group of patients with the aim of creating a 
representative sample of a specific group of lung cancer patients fitting the inclusion criteria 
for a chemotherapy trial (135). Sampling processes in qualitative research is most often not 
aiming at drawing a representative sample for generalizations of results. Participants in 
qualitative studies are rather selected intentionally or strategically, i.e. the investigator invites 
participants according to their knowledge about the topic investigated in order to include 
informants that represent the most typical or the maximum variation of the field of 
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investigation (161), page 230 ff.. In other words, in qualitative sampling processes, the investigator 
usually searches for the participants he needs, whether it is all kinds of patients or only those 
who probably have sufficient experience to give relevant information about the topic of 
research. 
Different sampling strategies might be chosen within qualitative research. Since the aim of the 
POP trial was to explore the experiences of a particular group of patients  severely ill cancer 
patients  a so-called homogenous sampling would probably have been used, i.e. selecting 
informants due to their similar characteristics relevant for the research question (103, 122). This 
would probably have resulted in a sample quite similar to the one actually drawn in the POP
trial.   
Also regarding the number of participants, the principles for quantitative research were 
followed, since the number of patients was decided in advance based upon power calculations 
for the PEG trial In qualitative research the inclusion process are usually closed when one 
reaches saturation (135). Since quite a few of the interviews did not provide sufficiently rich 
information about the topic, it is considered that saturation probably not was reached when 
the inclusion period was over. However, that saturation was not reached was probably not a 
result of the sample size being too small, but of some limiting aspects of the interviewing 
process (see section 6.2.3). Furthermore, the principle of saturation is not the most suitable for 
all qualitative studies. In the POP trial, the final number of participants was decided due to 
the pragmatic aspect of how many eligible informants were available in the project period. 
Eleven of the eligible participants were either not asked or refused to take part in the POP 
trial. No further information was collected about the characteristics of these patients, their 
reasons for refusing or the reasons for someone not being asked. The inclusion criteria for the 
PEG trial, and thus the POP trial, were rather stringent, and the eleven patients were thus 
probably quite similar to the included patients.  
Documents (papers III and IV) 
The samples of ICDs used in the two document studies in this thesis (paper III and IV) were 
collected from the archives at the regional ethical review board in the Central Norway, and 
thus represent only one region of the country. All the ICDs were related to cancer research, 
and might not be representative for ICDs from other medical fields.   
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The 87 ICDs in paper III 
The study in paper III is a quantitative study, and the sample of 87 ICDs was randomly drawn 
to comprise a representative subsection of cancer research ICDs submitted to this ethical 
committee, and is regarded representative for all cancer research ICDs approved by this 
committee in the entire period from its establishment until 2007 when the data collection was 
done. It is not considered representative for ICDs approved later than the inclusion period, 
since a considerable change in the national regulations of ICDs took place in 2009 when a 
template was developed (see section 6.3).   
The sample of ICDs is not necessarily representative for ICDs submitted to the other 
Norwegian regional ethical committees, since the procedures for reviewing ICDs may vary 
between the different committees, and the cancer research activity within the four Norwegian 
health regions might also differ. However, the variation was probably larger in the beginning 
of the period, and reduced over the years due to an increasing level of standardisation of 
regulations concerning the content of ICDs. 
Neither is the sample regarded representative for international ICDs since the procedures for 
writing and reviewing ICDs may vary between countries, even though the international 
ethical regulations for clinical research are the same across the world and have strongly 
influenced the Norwegian regulations in the field (96).
The 20 ICDs in paper IV 
The size of the sample for the follow-up study (paper IV) was based on the number of 
documents analysed in the studies by Clerehan and colleagues (32, 33) who developed and made 
use of the Evaluative Linguistic Framework (ELF). They included a sample of 18 documents 
from a previously examined corpus of 91 (33). The selection of 20 ICDs in paper IV was 
regarded as both a manageable and large enough number of documents for the broad 
linguistic analysis of text quality. The sample was not selected to be representative but to shed 
light on the development over time (135).
As mentioned above, the variation between the ICDs approved in different committees was 
probably larger in the beginning of the inclusion period. Thus, the 10 oldest ICDs in the 
sample are less likely to be representative for other ICDs in country, while the 10 newest are 
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more likely to be representative for all ICDs approved in the region, and also all Norwegian 
ICDs, from 2006-2007. Additionally, the 10 oldest ICDs in paper IV were rather homogenous 
and it was often obvious that they were written by researchers belonging to the same research 
group (based on the names and institutions mentioned in the ICDs). The consequences of 
using a homogenous sample of ICDs might be that aspects of functional readability in earlier 
ICDs would not be identified. Samples consisting of ICDs from other committees or other 
countries may have resulted in identifying other aspects that contributed to increased or 
decreased readability.
Previous empirical studies (paper II) 
The four databases chosen for the literature search were regarded as relevant databases and a 
sufficient number of databases to retrieve as many empirical studies as possible. Still, one 
cannot guarantee that some articles were missed in the search. One might assume a database 
like CINAHL could have yielded additional relevant paper, since studies of informed consent 
often have been published in nursing research journals (11, 75, 127, 141-143, 186). A literature search 
in CINAHL with the same search terms and within the same period as in paper II actually 
yielded 81 hits, of which 25 were not identified in the original search. However, none of these 
were eligible for the systematic review.  
The search term understanding was used in the search string because the Declaration of 
Helsinki states that it is the physician’s responsibility to ensure “that the potential subject has 
understood the information” (224). The term comprehension was included because it is the 
MeSH-term that covers understanding. In the included studies the respondents were asked to 
answer questions regarding what they had grasped from the information that had been 
disclosed to them concerning the study they were participating in or were eligible for. As 
described in paper II, several terms and descriptions were used for the phenomenon being 
measured, and most often without a definition, for instance recall, retention and knowledge, 
even if these were not included in the search string. In retrospect, one might question why the 
search was not altered to include these terms as well. An extended MEDLINE search for 
studies published the same period as the included studies, and with the terms knowledge, 
recall, retention, and memory was therefore performed, and this search yielded 1552 hits. A 
comparison was made between the hits in two time periods, 1995-1996 and 2005-2006, in the 
original search and in the extended search. The extended literature search yielded a total of 
453 hits in the two time periods, compared to 187 in the original search limited to the same 
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period. However, only two includable papers were identified, of which one had already been 
identified in the ISI Web of knowledge and one through the hand search. In conclusion, it is 
thus most probable that the initial literature search and hand search identified the vast 
majority of the relevant papers in the field published between 1969 and 2007.
6.2.3 Interview validity (paper I) 
The interview guide was not developed by the interviewer, but by the co-authors. It consisted 
of questions assumed to be useful for initiating a discussion with the patient about the 
informed consent document (presented in section 4.1.2). Most questions in the guide were 
closed-ended questions (yes/no). It might have yielded richer information if open questions 
had been used. However, the follow-up questions were used to allow the informants to 
elaborate upon their views.
The interview guide was developed based on an image of a patient who was able to express 
various aspects of his/her experiences and reflections related to reading the ICD. In the 
interviews it turned out that it was rather difficult for many of the patients to answer the 
questions, and the material turned out to be not as rich as assumed. Rich information or “thick 
descriptions” are a condition for a higher degree of transferability of qualitative research 
results (45). The question about the language in the ICDs did not yield any substantial answers, 
and is left out of the presentation of results in paper I.
After the first interview, the interviewer changed the guide so that each interview started out 
with one open-ended question about what the patient thought of reading the ICD. A trained 
interviewer would probably have altered the interview guide to a greater extent in advance, 
for instance to systematically include more open questions related to the ICD and the consent 
consultation (such as "who gave you the ICD?", "when did you receive it?", "what did the 
doctor tell you?"). This might have helped the patients to think through the entire process as a 
basis for answering the questions and also contributed to placing the patients’ answers into a 
broader context during analysis.
In the POP trial it was regarded suitable that the first author with a background from 
communication research undertook the interviews, and not a physician or nurse. This was 
assumed to contribute to staying focused on the topic at hand during the interviews (the 
content of the ICDs) and prevent talking about diagnosis and treatment. 
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However, since most of the interviews were conducted at the lung department, the interviewer 
was instructed to wear a white coat. This coat probably affected the conversation, since 
several of the informants seemed to talk to the interviewer as a health care professional, i.e. 
asked questions related to treatment procedures, even though the interviewer presented herself 
and explained that she was not a nurse or a physician. The patients answer might have 
differed if the interviews had taken place outside the lung department or the hospital. On the 
other hand, the patients asked several questions which seemed to be directed to a 
nurse/physician which indicated clearly what kind of information they wanted – and to learn 
what the patient wanted was a major aim in the POP trial. 
In order to ensure a consistent, reliable data set, the same person conducted all the interviews. 
The interviewer also transcribed all the interviews. Transcription reliability was maintained 
by doing a verbatim transcription, not a retelling or summary, and by always going back to 
recordings during the rest of the analytic process when uncertainly occurred concerning what 
had been said. 
6.2.4 Data extraction schemes (paper II, III and IV) 
Three different data extraction schemes were used in this thesis, one in the systematic review 
(paper II) and in the two document analyses (paper III and IV). For the two document 
analyses, relevant available methods for data extraction were not found. In paper III, an ad 
hoc scheme for content analysis was developed by the investigators, while in paper IV, a 
framework developed for a similar research setting involving written patient information (32-34)
was used. 
Data extraction scheme for systematic review (paper II) 
In accordance with the aim of the systematic review, the data extraction scheme needed to be 
extensive and detailed in order to achieve a reliable method and a valid analysis. This would 
enable the investigator to identify the differences concerning the terms and the instruments 
used. A scheme with fewer, overall categories would not have given the possibility to 
describe the nuances in the included studies.  
The 47-point list of mandatory content in ICDs (paper III) 
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In the process of developing the 47-point data extraction scheme in paper III, the guidelines 
from the Oviedo Convention from the Council of Europe4 was not addressed. Regarding the 
content of ICDs, the most relevant part of the Oviedo Convention is The Additional Protocol 
to the Convention on Human Rights and Biomedicine, concerning Biomedical Research (41),
which was published in 2005. The investigators were not aware of this publication at the time 
of the data extraction. The Additional Protocol contains a list of mandatory information for 
persons being asked to participate in research. Most of the elements in the Oviedo-list were 
already covered by the 47-point list. However, element (iii) “arrangements for responding to 
adverse events or the concerns of research participants” and element (vii) “any foreseen 
potential further uses, including commercial uses, of the research results, data or biological 
materials” do not have clear corresponding items in the list used in paper III. Including these 
would have increased the validity of the data extraction scheme, since the list would have 
been slightly more representative for the actual guidelines. However, it is considered that 
including these elements in the scheme would not have changed the results of the analysis. 
In a subsequent study, the 47-point-list was used to develop a questionnaire (117). Through a 
Delphi-process (95), the number of elements was reduced from 47 to 30 . During this 
procedure, it became clear that there were quite a few overlapping elements in the original list 
of 47 items that had not been excluded during the initial discussions. This means that a few 
elements in the 47-point list were not sufficiently precise.
A limitation regarding the 47-point-list is that it comprised of mandatory elements from about 
2005 – when the analysis was initiated – while it was used for analysing ICDs from the entire 
period (1985-2007). However, it would have been nearly impossible to analyse the ICDs from 
each period in accordance with the corresponding guidelines, since the development and 
management of ethical guidelines are a continuous processes which are not possible to date 
accurately.
The Evaluative Linguistic Framework (ELF) (Paper IV) 
The ELF’s face validity was assessed by the co-authors and found quite satisfactory. The 
items included in ELF were considered appropriate for analysing ICDs in order to identify 
what constitutes text quality, functional topic organization and also possible sources of 
4 The guidelines from the European Convention on Human Rights and Biomedicine of 1997  
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confusing information, i.e. information not functional, for the eligible research participant 
reading it. Despite similarities, there are, however, some key differences between the two 
genres: A drug information leaflet is written to provide supplementary information about a 
particular therapy (33), while an ICD is written to facilitate the readers’ choice concerning 
taking part in medical research. However, the different aims do not make the ELF unsuitable 
for investigation of ICDs.
The ELF was developed through re-examinations of different documents within the same 
genre, of subsamples and of extended material (32-34, 100). Two studies were conducted to 
validate the framework by the constructors. The results in the first one showed that patients 
preferred documents written in accordance with ELF, with respect to both linguistic and 
design considerations (100), while the conclusion in the other one was that: “We believe that 
use of our framework may be both valid and valuable for assessing and enhancing the quality 
of other medication information documents” (34).
At least one relevant aspect of ICDs was not covered by ELF: the amount of information 
given for each topic, something which turned out to be of relevance for analysing text quality 
of ICDs. Not only an increasing number of topics, but also an increasing number of details 
contributed to the new ICDs being longer. The old and new ICDs differed considerably when 
it came to the presenting details about study procedures. However, the ELF was not designed 
to cover this aspect. Still, the ELF is considered suitable for analysing text quality of ICDs in 
a more functional manner than quantitative readability indexes, which was the aim in paper 
IV.
6.2.5 Triangulation 
Deductive and inductive analysis of interview (paper I) 
To combine deductive and inductive categories in the analysis of the interviews were 
considered a strength since it made it possible to identify both the informants’ perspectives 
concerning the content of the ICDs and the most relevant surrounding aspects that could 
explain why the informants acted and reflected the way they did. To investigate the 
interaction between the phenomenon being studied and its context is especially important in 
qualitative research which is oriented towards understanding what has happened in a specific 
situation than towards producing results that are generalizable to larger populations (81).
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Quantitative and qualitative document analyses (papers III and IV) 
Combined, the two document analyses (papers III and IV) might be seen as a methodological 
or analytical triangulation of the same phenomenon (199). The aim of combining 
methodological strategies in the analyses of ICD was not to reach identical results or to 
confirm the initial finding with the next. Rather, inconsistent or even contradictory findings 
are to be expected when triangulation methods for analysing the same data (137), and the aim 
was to complete investigators’ understanding of the content and design of ICDs (180). The 
results on the two studies were to a certain extent contradictory. The new ICDs were longer 
than the old ones, an aspect that previously has been related to reduced readability (12).
However, the longer new ICDs were found be more readable in certain aspects than the 
shorter, old ones. Since the length of documents was not an item in the framework used in 
paper IV, the combination of methods gave a more complete picture of ICDs.  
During the analysis using the ELF in paper IV it was discovered that the level of details 
concerning each topic would have been a relevant additional item for the study of text quality 
of ICDs. The document analyses showed an increased number of topics in the ICDs, which 
might explain why they have become longer. However, the extended level of details and 
elaborations regarding some of the topics in the newer ICDs is probably also an important 
part of the explanation of the increased length. Neither of the methods employed in paper III 
and IV covered this aspect. 
Co-researcher dialogue (all studies) 
The use of co-researcher dialogue (also called investigator triangulation (199)) was used to
various degrees in the studies in this thesis. The data extraction in all the studies was mostly 
done by the first author alone5, while it preferably should have been at least two co-workers 
collaborating also in this stage of the analytic process. Regarding for instance the use of ELF 
(paper IV), the application of the framework for a different document genre than is was 
originally developed should have included a critical review of each item and a collaborative 
data extraction.
Two authors discussed all the proposed elements in the list in order to reach an agreement 
about how to interpret them. A couple of elements were deleted from the list during this 
5 The first author was not the same person in paper III as in the other papers 
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process because discussion revealed that some categories were not actually content elements 
but style elements and thus not appropriate for the study. 
The interpretation phases of the analysis were done collaboratively. For instance, in paper I, 
two co-authors with different professional positions, communication and medicine, 
discussions resulted in the inclusion of an inductive analytic phase. It was considered useful 
for addressing the research question to include the patients' contextual experiences. This 
approach has been called "directed content analysis" (106, 228), meaning that the initial coding 
starts with a theory or relevant research findings, and then the researchers during the analysis 
immerse themselves in the data and allow themes to emerge from the data. In paper IV, the 
interpretation of textual aspects as increasing or reducing readability was done through 
discussions between two authors.
6.3 ICDs  present status 
In Norway, instructions about how to write ICDs are given in two new ICD templates 
developed by a working group within the ethical committees in 2009 (one general template 
and one for clinical trial ICDs). Thus, current ICDs might differ from the ones included in this 
thesis and that ICDs now are more standardized.   
In addition to content instructions, the templates include a suggestion for main heading 
(Request for participation in a clinical trial) and several subheadings (Background and 
purpose; What does the study involve?; Potential advantages, disadvantages and serious 
adverse events; What will happen to the samples and your personal information? and 
Voluntary participation). The templates consist of “fill in-sections” (with instructions 
regarding which content to insert) and of ready-prepared formulations which the writer might 
use in his ICD, for instance  
- This is an invitation for you to participate in a research study which involves testing of 
the medicine
- The samples and data that are registered about you will only be used in accordance 
with the purpose of the study as described above
- Participation in the study is voluntary. You can withdraw your consent to participate 
in the study at any time and without stating any particular reason
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The template consists of three parts. The first part is a description of the main procedures and 
the participant’s main rights, and is supposed to give the reader sufficient information to make 
a decision. Part two and three are appendixes with elaborations for readers who want more 
information. Part two is meant for elaboration of what the study involves while part three is 
meant for information about data privacy, biobank, funding and insurance. There are no 
further instructions given to the author about what to include in the appendixes. The consent 
declaration is placed in the end, after the second appendix. Thus, an increasing amount of 
instructions about what and how to write are provided to Norwegian writers of ICDs. The vast 
majority of the instructions concern the ICDs’ content, not the shape.   
Another major change in the field of research ethics in Norway in 2009 was the 
implementation of the new Act on medical and health research (Health Research Act) (147) . 
The Health Research Act contains the first general, statutory provision of consent to medical 
research in Norway and states that, as the main rule, the consent should be informed, 
voluntary, explicit and documentable (147) (chapter 4, § 13). However, the Act does not specify 
how one might ensure that participants are informed.  
The practical implications for the writing of ICDs are that fewer authorities now are involved 
in the process of approving the documents, but still there are quite a few possible involved 
parts in the process of approving an ICD, especially regarding clinical trials (drug testing). 
For studies involving drug testing, the researcher is required to send an application to the 
Norwegian Medicines Agency which might comment upon the ICD, and which rather often 
does (personal communication with Kari Steig, Norwegian Directory of Health). Studies 
involving clinical testing of medical equipment have to be reported to the Norwegian 
Directory of Health, which also might make objections concerning the content and language 
in the ICD, but which rather seldom does (personal communication with Ingvild Aaløkken, 
Norwegian Medicines Agency). Finally, pharmaceutical companies initiating clinical trials 
have developed their own templates for content and design of ICDs which might differ from 
the new template.   
Even though paper IV showed that length is not a sufficient factor for predicting readability, it 
is still considered a problem that the ICDs are long. Norwegian ICDs have usually been 
shorter than ICDs from several other countries (ICDs from about 35 countries were collected 
for a planned comparative study with a similar design as in paper III), but have still been 
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considered too long. The new template for ICDs was designed to give the reader a relatively 
short overview of the most important information. However, the possibility to include 
elaborations in part two and three had led to ICDs becoming much longer than before 
(personal communication with Arild Hals, REC Central Norway). And the placement of the 
actual consent declaration, i.e. the place for the signature, after the two appendixes, might 
indicate to the reader that the entire information should be read before a decision is made. A 
thorough oral explanation of how to deal with the ICD would be necessary.    
6.4 Study implications 
Implications for practice and implications for future research are presented below.  
6.4.1 Implications for practice 
In this section, some implications for those who review and approve/disapprove of the ICD, 
i.e. members of ethical review boards (called REC members), and those who write ICDs, i.e. 
medical researchers, are presented.   
Implications for ethical review boards 
- The results in paper I showed that some contextual aspects are of great relevance for 
how severely ill patients might perceive the ICD. The unfamiliar and frightening 
situation they were in and their confidence in their physician made the information in 
the ICD of less importance for them in the consent process. Thus, also REC members 
should take the contextual aspects into considerations in their review of the ICDs.
- The results of the document studies (paper III and IV) indicated that REC members 
need to take into considerations a broad range of textual characteristics in their review 
of ICDs, for instance overall thematic consistency, emphasizing important messages, 
suitable headings and subheadings and clarity of interaction between the actors. 
REC members administer ethical guidelines such as the Declaration of Helsinki, ICH Good 
Clinical Practice and the Oviedo Convention. Thus, one might say that in order to enhance the 
ICDs, there is a need to revise these guidelines as well, not only recommend changes in the 
REC review process.
The guidelines for authors of ICDs often comprise lists of essential/mandatory content 
elements (examples shown in section 2.1.2). In these lists each content element seems to be 
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equally important, since no information is given regarding what is the most important 
information or the overall message to the reader of the ICD.  
Based on the findings of studies, the following would be possible elaborations of the 
guidelines for trial information to eligible trial participants: There is a need:  
- to specify what is the main objective or function of the information to eligible 
research participants (in order to orient the content and design of the information 
towards this) 
- for a certain ranking of the required content elements in order to specify which are 
the main topics 
- to include more guidelines concerning how to present the content, i.e. how to 
present a large amount of required content in an adequate manner for a patient 
audience
- to elaborate how the physician is supposed to ensure that the patient has 
understood the information and a specification of what is the most important 
information to understand 
A more radical approach related to the challenges of writing understandable ICDs, is the 
question of whether written information at all is an appropriate solution for obtaining 
informed consent. Alan Meisel argues that ICDs are merely formalistic and that what is 
needed is methods of informing patients adjusted to each person’s needs and learning styles 
(144). Consequently, this means to aim for individualization of information rather than 
standardization of the information. Individualization is not achieved through written 
information, but through “good, old-fashioned conversations”, according to Meisel (144). Other 
investigators in the field of informed consent has also found or argued in favour of 
conversation as the way of ensuring the patients’ understanding during the consent process 
(215, 229). While it is unlikely that written information would be totally replaced by oral, these 
points of view suggest that the guidelines for information to eligible research participants also 
might specify how to inform the eligible participants orally. 
Implications for writers 
The results of the studies in this thesis and previous research might contribute to suggestions 
for what to bear in mind when writing ICDs for potential research participants. A consistent 
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and functional ICD should be oriented to the overall aim of the informed consent process. The 
ICD might have different aims for the writer and reader, but ideally, the ICD is written for the 
eligible research participant, and the aim is to enable the reader to make a truly informed 
decision about participating in research. In order to write a functional ICD, one might:  
- Emphasize research as main topic in the ICD, i.e. present the request to participate, 
the study procedures (not the treatment per se), the choices the reader has, the 
implications of choosing one or the other, including the reader’s rights. Patients 
might want a lot of information about their disease, treatment and prognosis. In the 
consent process, however, this information should be framed as part of a research 
setting in order to be functional.
- Clarify the relationship between the reader, the writer and any additional actors in 
the document, for instance by explaining the dual roles of the physician and patient 
(i.e. that they are also an investigator and an eligible research participant).  
- Emphasize the request to participate as main function. The information in the 
consent process is related to subsequent actions, first and foremost the consenting 
(or refusing), performed by the reader. The main function might be clarified by 
placing a request in the beginning of the ICD, by repeating the request, and by 
giving the reader clear instructions about how to proceed if he/she wants to 
consent.
- Clarify what actions the different persons are supposed to perform might be 
clarified by writing in the active voice and include subjects in the sentences.
- Orient the ICD towards the target reader, i.e. the eligible research participant, not 
“only a patient” and not the ethical review board. 
Furthermore, since it is the investigator's responsibility to ensure that the trial participant has 
understood the information, a test of participants’ understanding might also be used as part of 
the actual consent process (213). Relevant questions in such an assessment tool should address 
the overall aspects of research and the study, for instance the aim of research, the aim of the 
specific study, and how research differs from regular treatment. There are some examples of 
questions of this kind in studies included in paper II:
- Items regarding the goals of the study were for instance included in the 
questionnaire developed by Strevel et al: Please state whether each of the 
following is a goal of a phase I clinical trial: a) decide how much of a new drug 
can be given safely (yes/no), b) decide how often a new drug needs to be given 
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(yes/no), decide if a new drug is more effective than an old drug (yes/no), decide 
what the side effects of a new drug are (yes/no) (192).
- The questionnaire developed by Joffe and colleagues, the QuIC, addressed the 
main aim of cancer clinical trials, and emphasized the important aspect of trials 
being performed to benefit future patients (A2. The main reason cancer clinical 
trials are done is to improve the treatment of future cancer patients (Disagree, 
unsure, agree)) (116).
- The questionnaire developed and validated by Hutchison and colleagues consisted 
entirely of questions about research (since it is designed to test patient 
understanding of research). Questions in the questionnaire look like this: The main 
reason for carrying out research with patients is … (a) to improve current 
treatments; (b) to find treatments with no side effects; (c) to help pay for cancer 
treatments; (d) don’t know.
- Hutchison et al’s questionnaire also addressed the crucial differences between 
therapy and trials in the options for response in the following question: When a 
trial is ‘randomized . . .(a) the process selects the best treatment for you; (b) you 
have exactly the same chance of receiving the new treatment (or not receiving it), 
as any other patient taking part; (c) the doctor decides which treatment is the right 
one for you; (d) don’t know.
6.4.2 Implications for research 
Future research of ICDs would have to imply the studies of both the readers, writers, approval 
authorities and the documents in order to facilitate the readers’ understanding of the 
information to a sufficient level for voluntary decision-making.  
- There is a need to investigate how to organise the information so that the readers 
are capable of sorting out the main message of an ICD. 
- In order to compare the level of understanding of documents with the same 
objective, there is a need for a standardized assessment tool based on a common 
definition of the term “understanding”. In order to measure the participants’ 
understanding of the information, there is also a need to specify the overall 
message and the overall aim of ICDs. (See recommendations in section 6.4.1.) 
- A broader approach to the consent process would also have to include research on 
the oral information about medical research to the eligible participants. 
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- Two important organizational changes have occurred since the data collection in 
this thesis was done: The introduction of an ICD template and the implementation 
of the Health Research Act (see 6.3). The direct consequence of writers using the 
template is that the ICDs become even more standardized, but the template per se 
is no guarantee for more readable ICDs. Thus, a relevant subsequent research 
question is how these changes have affected the length and the functionality, 
including the readability, of Norwegian ICDs?  
- It is still not known what kind of ICD modifications/revisions that increases the 
reader’s level of understanding. Further studies would have to imply intervention 
studies of linguistically based modifications of ICDs and of information oriented 
towards patient’s information preferences 
- Future modifications of ICDs should be completed with performance-based 
approach as for instance user testing. To combine performance-based user testing 
with expertise in writing for patients and information design resulted in a 
significantly improved and preferred information sheet in a study by Knapp and 
colleagues (123).
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7 Conclusions 
The following conclusions are the answers to the research questions addressed in the thesis:
- After reading an ICD, the patients were most concerned with practical and detailed 
information about the treatment they were about to receive – summarized as ”who will 
do what, when and where”. They were, however, aware of their participation in 
research and that the overall goal of research is to generate new knowledge which 
might benefit future patients. The patients expressed less interest in information about 
research formalities. 
- Both the patients who read the standard ICD and those who read the shortened 
version, expressed satisfaction with the amount of information. Few patients were able 
to state which information was redundant and what they would have preferred to read 
more about. The two participants with higher education were the only ones who were 
able to state their opinion about redundant information.  
- The term ‘understanding’ has seldom been defined in previous studies of research 
participants’ understanding of information. Previous studies showed a large varition in 
the terms used for the phenomenon measured; terms such as understanding, 
comprehension, recall, knowledge, awareness, preception, retention etc. were often 
used  synonymously within the same paper. 
- Previous studies of understanding were very heteregeneous in terms of participants 
included, number of participants, the timing of mesuring and not least the assessment 
tools used, which in most cases was developed for each study. The most frequent 
assessment tool was questionnaires, and they differed substantially regarding the 
number of questions, the content of the items and the time of testing related to the time 
of information.   
- A threefold increase of length was found in Norwegian ICDs between 1987 and 2007. 
- The number of content elements in Norwegian ICDs increased considerably from 
1987 to 2007. The presence of both basic elements and formal elements had increased, 
with the largest increase identified for the formalities.  
- Overall textual characteristics that might contribute to increased readability of ICDs 
are: to introduce the document be clearly referring to the main message of research 
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participation and implications, to maintain this thematic focus throughout the entire 
ICD, and to write for the main reader – i.e. the eligible research participant, not merely 
a patient and not the ethical review board 
- Even if the new ICDs were longer than the old ones, they were not necessarily less 
readable. New ICDs were more clearly oriented towards the main topic and function 
of ICDs, since the request to participate were placed in the beginning of the 
documents, and since the entire documents were more oriented towards research 
procedures and implications. The old ICDs, on the other hand, presented a clearer 
interaction between the actors in the document, for instance due to less additional 
actors.
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1. Introduction
Before inclusion into biomedical research, researchers must
obtain the informed consent of the eligible patients. The
information in the trial includes both verbal and written elements,
and a truly informed consent presupposes that the patients can
understand written information before signing the consent
document.
The Declaration of Helsinki recommends that the consent
document should include information about the purpose of the
trial, procedures, possible risks and beneﬁts, sources of ﬁnance,
potential conﬂicts of interest and the researchers’ institutional
afﬁliation [1]. In addition, the documents should be written in
accordance with directions from the Regional Committee for
Medical Research Ethics, the Norwegian Social Science Data
Services, and the Norwegian Medicines Agencies. The amount of
directions for content in the consent documents has increased over
the last years, and it could be a challenge to comply with all these
instructions when writing a consent document.
Previous studies have revealed that many participants in
clinical research fail to understand or recall central aspects in the
information disclosed during the consent process [2], like risks,
the right to withdraw [3], conﬁdentiality [4], side effects [5] and
the purpose of the trial [6]. Suggested explanations for this have
been low literacy in some patient groups (e.g. high age and lower
education), low health literacy among typical underrepresented
groups in clinical research (e.g. ethnic minorities), the patients’
reduced health status, and technical and scientiﬁc language in the
consent documents [5,7,8].
Another explanation for participants’ lack of understanding
might be that the extensive instructions for writing consent
documents result in complex documents consisting of too many
elements of information. The amount of information could limit
the readers’ ability to understand the main point of the consent
document and to give a truly informed consent.
In order to enhance informed consent documents, it is
important to study how the patients themselves perceive the
documents. To our knowledge no studies have addressed which of
the information elements the patients perceive as most relevant
and important. Further, most patients are severely ill and elderly,
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and little is known about how sick, weak or old people perceive
complex consent documents and which of the content elements
they regard to most relevant.
In the present study, we compared patients’ perceptions and
preferences of two different versions of informed consent
documents written according to a set of formal requirements.
Our primary research question was which content the patients
considered relevant or important. A secondary question concerned
the amount of information—did the patients ﬁnd any of the
information redundant?Or did they prefer additional information?
2. Methods
2.1. Intervention
The subjects were eligible for a randomized, phase III study by
the Norwegian Lung Cancer Group comparing pemetrexed plus
carboplatin versus gemcitabine plus carboplatin as ﬁrst line
chemotherapy of patients with stage IIIB/IV non-small cell lung
cancer (the ‘PEG’ trial) [9]. The original consent document for the
trial contained 1118 words, and was approved by all regulatory
authorities (the Regional Committee for Medical Research Ethics,
the Norwegian Medicines Agency, Norwegian Social Science Data
Services, and the Directorate for Health and Social Affairs) in 2004.
For the purpose of the present study a shortened version of the
consent document, containing 508 words, was written. The
shortened version was based on a consent document written for
a study with the same design in the same patient group approved
by the Regional Committee for Medical Research Ethics in 1994.
The content was modiﬁed in accordance with the PEG trial.
The two consent documents consisted mainly of two categories
of information. We have chosen to term the information
concerning the study treatment and the study related procedures
as medical aspects, and the information not directly related to
treatment and procedures as formalities. Formalities would be for
instance information about conﬁdentiality, storage and possible
re-use of data, consequences of refusal or withdrawal of consent
(alternative treatment, whether collected data will be deleted or
not), access to the results after the trial is closed, and insurance.
The distribution of the two main categories of content in the two
consent documents is shown in Table 1.
Both documents consisted of detailed information about the
treatment procedures: beforehand procedures, how information
about the patients will be recorded, randomization, frequency and
duration of the treatment, medication not to be taken during
treatment, which information will be collected from the patients,
and exclusion criteria. The original document in addition consisted
of thorough information about what will happen to the collected
data (storing, deleting, conﬁdentiality and publishing), about who
is responsible for and ﬁnancing the study, and about the different
approving authorities.
2.2. Interviews
After having received verbal information about their malignant
disease, recommended treatment and the purpose of the PEG trial
from their physician, consecutive patients eligible for the PEG trial
at St. OlavsHospital, Trondheim, Norway between September 2005
and July 2006 were asked to participate in a semi-structured
interview. Of the 33 eligible patients, 22 agreed to participate in
the interviews. They were randomly assigned to receive either the
original consent document or the shortened version before the
interview. The eleven others were either not asked or refused to
participate.
All the interviews were undertaken by the same interviewer
(K.S.). The interviews took place at a minimum of 90 min and a
maximum of 30 h after the patient had received the informed
consent document. One of the interviews took place 3months after
enrolment, and was later excluded. This yielded a ﬁnal material of
21 interviews. The patients had the consent document available
during the interview. All patients read and signed the original
consent document before they were enrolled in the PEG trial.
The six-item interview guidewas designed for this study to elicit
the patients’ own assessments of the information in the consent
document (Fig. 1). Follow-up questions were used for clariﬁcations
andelaborations.According to the semi-structureddesign, the items
were used as topics to guide a discussion with the patients.
Eighteen of the interviews were audio taped and transcribed
verbatim by K.S. For the remaining three, technical problemsmade
the audiotapes unusable, but thorough notes were taken during or
after these interviews.
2.3. Ethics
The studywas approved by the Regional Committee forMedical
Research Ethics.
2.4. Analysis
Data were analysed using methods of qualitative content
analysis, which included subjective and systematic interpretations
Table 1
Medical aspects and formalities in the two consent documents
The original document The shortened document
The medical aspects 823 words 458 words
The formalities 259 words (23.2%) 50 words (9.8%)
Other 36 words
Sum 1118 words 508 words
Fig. 1. The interview guide about here.
K. Sand et al. / Patient Education and Counseling 73 (2008) 313–317314
of the content of text data through identiﬁcation and categorization
of essential themesandpatterns [10–12]. Thedatawas analysedand
interpreted by the interviewer (K.S.) and one of the co-authors
(J.H.L.). The analysis was based on both deductive and inductive
categories [13]. The deductive categorieswerepredeﬁned according
toour researchquestions, andconcerned thepatients’perceptionsof
the consent documents. The inductive categories were developed in
terms of thematerial itself. Both kinds of categories were developed
through cooperation between the authors.
Initially the transcripts were read and re-read in order to get an
overall impression of the content. Thereafter, brief summaries of
each interview were written. Based on the summaries and the
recordings we identiﬁed and condensed the patients’ answers to
the questions outlined in the interview guide into overall answers
(the deductive categories). According to the randomized design of
the study these answers were compared for the two groups
of patients in order to detect possible differences. The second part
of the analysis was based on the sample as a whole, and included
recurrent themes that emerged as a result of inductive category
development [13].
3. Results
3.1. Patients
Twelve men and nine women participated. Ten received the
standard consent document and eleven the shortened version.
Background information about the participants in the two groups
is presented in Table 2. The subjects’ median age was 69 years
(range 44–84). All patients were considered decision-competent
by their physicians. The interviews lasted between 6 and 42 min
(median 12 min).
3.2. Deductive categories
Most participants were not able to assess the content in the
documents when they were questioned directly about their own
perception. Most gave short answers, for instance that the text was
all right, easily understood, and not complicated to read.
Interviewer: Do you think the document gives you the
information you need in order to ﬁnd
out whether you want to participate
in the study or not?
Patient: No I don’t know. . .not really
Interviewer: You would have wanted some more
information?
Patient: mm
Interviewer: About what. . .could you say something
about that?
Patient: No. . .I don’t think so
When asked what was the most important information in the
consent document over half the participants said that it was
important to know that they are contributing to science and
helping future patients. Other aspects that were brought up as
important information from the patient’s point of viewwere hopes
for better treatment (three patients), practical information about
the procedures of the trial (two patients), and information about
that the two treatment alternatives are equal (one patient).
Formalities, like voluntariness and the right towithdraw,were also
mentioned as the most important information. Some mentioned
more than one element as important, for instance both to help
others and to achieve personal beneﬁts.
3.2.1. Assessment of the amount of content
Seven patients answered that they wanted further information.
Three wanted more information about the medication/treatment
and the (side) effects of it. One was interested in the results of the
study. One wanted information about who he could contact, and
another wanted an explanation of the term ‘‘your doctor’’. The last
patient was not able to specify what kind of further information
shewanted, but said she would have preferred the text to be better
oriented for the general reader.
Two patients had a comment concerning redundant informa-
tion (the only two with higher education). Both of them read the
original version of the consent document. One said that some
elements probably could be removed from the text, but that it
would depend on each patient’s degree of illness what kind of
information that would be experienced as unnecessary. The other
found the detailed explanations in the document unnecessary.
3.2.2. Assessments of the formalities
Eleven patients stated they did not need to read about the
formalities. Seven other patients said that the formalities were
interesting or relevant. Some of them added that they preferred to
receive as much information as possible, but most of them did not
extend their opinions about the formalities any further. The last
three patients did not have a clear answer to the question.
Two patients, who read the original consent document,
reﬂected any further on the formalities on their own initiative.
One characterized the formalities by saying: ‘‘The rest of the text [i.e.
the formalities] is something that I haven’t tried to memorize or
assess. It is that kind [of information] that I will deal with if necessary’’,
thus indicating that he had not read the formalities as thoroughly
as the rest of the text. The other brought up the formalities while
explaining how she would have separated the two parts, and put
the medical aspects on one page and the formalities on another—
‘‘because then you could choose to readwhatwas themost relevant for
you’’.
She also reﬂected on how she thought the average patient
would read the formalities of the documents, by saying: ‘‘When
they read it. . .there are a lot of questions that they don’t ask
anybody. They don’t. I don’t think so. It doesn’t occur to them that
they can ask about this. Where it [the data] will be stored for 15
years—it doesn’t matter’’.
For the rest of the patients, the formalities were not perceived
as a problem, but rather as insigniﬁcant. None of them brought up
issues like publishing, ﬁnancing, insurance, or approving autho-
rities, which are required elements in a consent document.
3.3. Inductive categories
Three essential themes were identiﬁed during the inductive
analysis of the interviews: the patients’ trust in their physicians,
the unfamiliar situation at the hospital and the questions raised by
the patients during the interviews.
Table 2
Background variables in the two groups
Standard informasjon Short information
Age (median, range) 73.5 (53–84) 68 (44–80)
Gender (males/females) 8/2 4/7
Education
Primary and/or lower
secondary school
5 5
Between 1 and 3 years
of upper secondary education
4 5
More than 4 years of
higher education
1 1
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3.3.1. Trust
Eight patients expressed complete conﬁdence in the physicians
and the hospital. When asked whether he wanted any further
information, patient 11 said ‘‘No, there is not (. . .) because I am in
the best hands when I take part in this’’. Other patients said that
they felt they were they could leave everything to the physicians
or that they knew the physicians would act in the patients’ best
interest. Some added that it was not crucial for them to remember
every detail of the consent document due to this conﬁdence.
The patients’ trust in the physicians was the most frequent
reason stated for their lack of interest in the research formalities in
the document. Seven of the eight patients who expressed
conﬁdence in the physicians, said that they did not need or want
to read about research formalities in the consent document.
3.3.2. The unfamiliar situation
The patients’ answers showed that being seriously ill and being
at a hospital was unfamiliar, something which might inﬂuence
their ability to understand written information. One said that the
consent document could be difﬁcult to understand because ‘‘all
this is new for me (. . .) and therefore it is difﬁcult to understand at
ﬁrst’’. Another answered that the much of the language in the
document was ‘‘completely Greek to me, I don’t have a clue about
chemotherapy’’. A third said that he left the illness to the doctors,
and ‘‘I don’t care. I have been healthy for 70 years, so this is
somewhat unfamiliar’’.
3.3.3. Questions raised by the patients during the interviews
The interview data did not yield direct expressions of what kind
of information the patients found relevant or irrelevant in the
informed consent documents. When questioned whether they
wanted any further information in the consent documents, most of
the patients answered no. However, during the interviews 14
patients spontaneously posed a number of questions to the
interviewer, something which indicated that they actually did
prefer some further information, and also which information they
were most interested in.
Most of the patients’ questions dealt with the treatment
procedures. The most frequent question was at which hospital the
patient would receive his/her chemotherapy. Other typical
questions were: ‘‘Who can I call if something happens?’’, ‘‘How
often will I get treatment?’’, ‘‘Is my personal physician performing
the blood tests?’’, ‘‘What are my prognoses?’’, and ‘‘Will I lose my
hair?’’. Practically none of the patients’ questions addressed the
formalities in the consent documents.
4. Discussion and conclusion
4.1. Discussion
The present study indicated that the information in the consent
document concerning research formalities was perceived of as less
relevant compared to information about disease and treatment.
The comparison between patients who read the original
consent document and patients who read a shortened consent
document with fewer formalities showed few differences regard-
ing the patients’ perceptions of the documents. However, the
answers from two patients who read the original document
indicated that the detailed information about formalities is
perceived as of lesser importance in this particular reading
situation.
Which information a reader notices and remembers in a
document, can be related to textual aspects like the structure and
organization of words, paragraphs and information elements [14].
However, it can also be related to contextual aspects, like the
reading situation. The patients included in the present study read
the documents while facing a life-threatening disease. One patient
characterized the situation like this:
‘‘because what you are interested in isme. . .here. . .now. . .that is
what concerns you (. . .) the only thing people are interested in
is. . .what would this imply for me?’’
It is of course important that the patients understand the
procedures of the treatment they are about to receive. However,
there are central differences between receiving treatment inside
and outside of a clinical trial, which are crucial for patients to be
aware of before accepting or refusing to participate in a trial.
Research is conducted to generate knowledge that could beneﬁt
future patients, and not necessarily the patients that participate in
the actual trial. When patients are not able to see this distinction
between treatment and research, the result could be the so-called
therapeutic misconception [15]. Therapeutic misconception exists
when the subjects do not understand that the overall purpose of
clinical research is to produce generalizable knowledge, regardless
of the individual’s personal beneﬁt [16].
The patients in our study expressed conﬁdence in the health
professionals, something that made it less important for them to
understand the consent document in detail. Previous studies have
also revealed the same degree of conﬁdence in the physicians
[17,18]. Kass et al. [17] found that many of the subjects had made
up their mind about participation before they were given the
information, and that a difﬁcult document did not matter. They
perceived the details of the document as irrelevant. This was also
the case for the subjects in our study. In some cases the answers to
the patient’s questions were clearly expressed in the consent
document. This indicated that not all of them read the document
thoroughly or that they did not notice, understand or remember it.
Still, they wanted to participate in the PEG trial.
It might seem that patients’ relation to their physician is of
greater importance than the informed consent document in their
decision making process. One might therefore question why the
formulation of the consent documents is strongly emphasised in
the research approval process, while the verbal information is not.
There exist no guidelines or approval of the verbal information, as
is the case for written information. Especially for poor readers, one
might question whether other strategies than clarifying the
consent document could be used for ensuring understanding.
Further research might examine patients’ perceptions of verbal
and written information, respectively. The information can also be
presented in more interactive ways than the static informed
consent document by use of modern information technology.
Possible improvements need to be documented by empirical
research.
Some aspects of the present study might have inﬂuenced the
ﬁndings. Firstly, due to the sample size we have limited
possibilities to make generalizations.
Secondly, the sample consisted of a homogeneous group of
patients, i.e. elderly patients with advanced lung cancer. The
perception of the content in the informed consent documents
could have been different in other patient groups, for instance
younger and/or less severely ill patients, or healthy volunteers.
Schaeffer et al. [19] found that subjects with diseases of different
severities focused on and retained different aspects of experi-
mental protocols.
Thirdly, some of the interviews were short. It seemed difﬁcult
for some of the patients to talk about their own reading of a
document. Many of them might never have reﬂected upon
shortages or irrelevant aspects of a document. Consequently, it
might be challenging to talk extensively about these matters in an
K. Sand et al. / Patient Education and Counseling 73 (2008) 313–317316
interview. To overcome this, future studies can address more
speciﬁcally the relevance of each content element. In order tomake
comparisons between different information strategies, future
studies with a randomized design will probably beneﬁt from
using standardized assessment methods for measurement of
understanding [20].
4.2. Conclusions
The consent documents did not seem to function as intended
since many patients seemed to pay little attention to the research
aspects, and thus risked to misunderstand the main point of the
consent document. Statements from two of the patients indicated
that the information of the formalities is perceived as of lesser
importance than the information about medical procedures. The
formalities are not necessary information for making a decision
about participating in the trial, but could be relevant later.
4.3. Practice implications
The physician in charge of the treatment should be aware of his/
her importance for the patients in their decision making about
whether to consent to participation in clinical trials. This points to
the necessity of ensuring the quality of the oral information
disclosed during the consent process.
It is also necessary to rethink the structure of the consent
documents. Writing a consent document should primarily be
based on the readers’ ability to understand and to give consent
instead of a list of required information. The structure of the
documents should clarify what the eligible patients agree to when
signing the consent form: that they are asked to participate in
medical research and that the decision to participate is voluntary.
A possible structure could imply to place the formalities as a
separate part of the document.
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Abstract
Thegoalofaninformedconsentdocument(ICD)istoaskthereadertoparticipateinresearch,andtoexplain
theimplicationsofbeingaresearchparticipant.AnICDisreadableifitachievesthisoverallgoal.Theaimof
thisstudywastoinvestigatethereadabilityofICDslinguisticallyandtocompareoldandnewICDsinthis
respect.TwentyICDs(tenfrom19871992andtenfrom20062007)wereincluded.TheEvaluative Linguistic 
Framework(ELF)wasusedtoanalysethetexts.ELFincludesthefollowingitems:mainthemes,orderof
themes,rhetoricalfunctions,therelationshipbetweenreaderandwriter,metadiscourse,headings,expert
terminology,andvisualaspects.ThenewICDswerefoundtobemorereadablethantheoldonesastheywere
moreorientedtowardsresearch,containedinstructionsabouthowtoconsent,andprovidedclearcontact
information.AspectsthatreducedthereadabilityofthenewICDswerethelargenumberoftopics,detailsand
actorspresented.ThereadabilityoftheoldICDswasenhancedbyfewtopics,aclearpresentationofthe
involvedactors,andbrevity.However,theirreadabilitywasreducedbytheinclusionofavastamountof
informationaboutthereader’sdiagnosisandtreatment.

Introduction 
Informedconsentdocuments(ICDs)areacentral
componentoftheconsentprocessinclinicaltrials.
Previousresearchhasshownthateligibletrial
participantsoftenhavedifficultiesunderstanding
theinformationprovidedintheICDs(Criscione,
Sugarman,Sanders,Pisetsky,&StClair,2003;
Joffe,Cook,Cleary,Clark,&Weeks,2001;Lynoe,
Sandlund,Dahlqvist,&Jacobsson,1991;Schultz,
Pardee,&Ensinck,1975),whichmightleadto
invalidconsent.Forthepatienttocomprehendthe
ICD,thedocumenthastobereadable.
Traditionally,readabilityhasbeenmeasuredby
useofindexes/formulas(Baker&Taub,1983;
Goldstein,Frasier,Curtis,Reid,&Kreher,1996;
Grossman,Piantadosi,&Covahey,1994;LoVerde,
Prochazka,&Byyny,1989;Meade&Howser,1992;
Murphy,Gamble,&Sharpe,1994;Ogloff&Otto,
1991;Philipson,Doyle,Gabram,Nightingale,&
Philipson,1995;Rivera,Reed,&Menius,1992;
Sharp,2004;Tarnowski,Allen,Mayhall,&Kelly,
1990),i.e.quantitativemeasurementsbasedon,
forinstance,numberoflettersperwordand
numberofwordsandsyllablespersentence(e.g.
theFleschreadingeasescore(Flesch,1948),the
GunningFogIndex(Gunning,1952)andtheFry
scale(Fry,1968)).Readabilitystudieshavealso
oftenincludedameasureoftheICDs’totallength.
However,traditionalreadabilityformulasfailto
coveravarietyofaspectsofadocument’s
readability,forinstancetheorganizationof
content,visualdesign,andchoiceofvocabulary.
Suchaspectsmayalsogobeyondthetextto
encompassthereaders’motivationandinterest
forreading,aswellasbackgroundknowledge
aboutthetopicspresentedinthetext(Finnie,
Felder,Linder,&Mullen,2010;Meade&Smith,
1991;Peterson,Clancy,Champion,&McLarty,
1992;Pichert&Elam,1985).
Anaspectthatfurthercomplicatesthereadingof
ICDs,isthattheinitialreaderofthedocumentis
nottheeligibletrialparticipant,butthemembers
ofanethicalreviewboardwhomustapprovethe
contentanddesignofanICDbeforethetextcan
bepresentedtotheactualtargetreader,the
2personwhoistogivehis/herconsent.Thesewill
oftendifferfromtheprimaryreaderonaspects
suchasage,educationlevel,emotionalstatusand
motivation.
InthepresentstudyofICDs,readabilityisdefined
asamatterofadocument’sfunctionalityforits
audienceinaparticularsituation.Thisimpliesthat
anICDisreadablewhenthetextualcharacteristics
–i.e.thecontent,thestructure,theterminology,
andtheinteractionbetweentheactorsinthetext
–contributetofulfillingthegoalofthe
communication.Thegoalfromapatient’s
perspectiveistobeenabledtogivea
consent/refusalthatisactuallyinformed(Erlen,
2010).Thisimpliesthatthereadermustbeableto
comprehendthatheisbeingaskedtoparticipate
inresearch,thatheissupposedtomakea
voluntarydecision,theimplicationsofconsentor
refusal,andthatparticipatinginresearchdiffers
fromreceivingstandardtreatment.
Inapreviousstudy,weshowedthatthelengthof
ICDsandthenumberofcontentelementshad
increasedconsiderablyoverthelasttwodecades
(Berger,Grønberg,Sand,Kaasa,&Loge,2009).
Thesetwoaspectsmightcontributetoreduced
readability.Inthepresentstudy,theaimsareto
evaluatethefunctionalreadabilityofICDsandto
compareoldICDs(19871992)withnewICDs
(20062007)inordertoinvestigatewhetherthe
new,longerICDsaremoreorlessreadablethan
theold,shorterones.

Materials and methods 
Material
Thematerialinthisstudyconsistedof20ICDs
selectedfromasampleof87documentsusedina
previousquantitativestudyofICDs’lengthand
content(Berger,etal.,2009).TheICDswerefrom
oncologicaltrialsapprovedbytheRegional
CommitteeforMedicalandHealthResearchEthics
inthecentralregionofNorwayfrom1987to2007.
Forthepresentstudy,the10oldestICDs
(19871992)andthe10mostrecent(20062007)
ICDswereselectedforanalysis.
Analyticframework
InordertoinvestigatereadabilityoftheICDs
beyondthetraditionalreadabilityindexes,a
linguisticframeworkdevelopedforstudyingtext
qualityofwrittenhealthinformationforpatients
waschosen,theEvaluative Linguistic Framework
(ELF)(Clerehan,Hirsch,&Buchbinder,2009).ELF
wasdevelopedbyClerehanandcolleaguesto
analysethequalityandpossibleshortcomingsof
druginformationleaflets(Clerehan&Buchbinder,
2006;Clerehan,Buchbinder,&Moodie,2005;
Clerehan,etal.,2009).SevenitemsfromtheELF
wereusedinthepresentanalysis(presented
below).TwooftheitemsfromELFwerenot
included.Lexicaldensitywasexcluded,since–as
farasweknow–anumberforaveragelexical
densitydoesnotexistfortheNorwegianwritten
language;moreoverthisisaquantitativemeasure
whichisnotconsideredrelevantforthepresent
analysis.Further,analysisoffactualcontentwas
excludedsincethiskindofanalysisdemands
specificmedicalandresearchexpertiseconcerning
thespecifictrialspresentedinthematerial.The
includeditemswereasfollows:
(1)Genericstructurerefersto(a)theoverall
themes(e.g.“purposeofthetrial”,“study
procedures”,and“participants’rights”)and(b)the
orderinwhichthethemesarepresented.A
documentisconsideredreadablewhenthe
reader’sexpectationsconcerningcontentaremet,
i.e.whenthereaderrecognizesaconventionalset
ofthemesandtheorderinwhichtheyare
presented(Clerehan&Buchbinder,2006).
(2)Rhetoricalfunctionsinadocumentinfluence
howthereaderdealswiththetext.(Clerehan,et
al.,2009).Thesefunctionsmaybetoinform,to
explainandtoinstruct.Adocumentisconsidered
readablewhenthereaderknowswhattodowith
theinformation–merelyreaditandcomprehend
it,oractuponit.
(3)ReaderͲwriterrelationshiprefersto(a)howthe
actorsareaddressedand(b)whoisgiventhe
responsibilitytocarryouttheactionsmentionedin
thedocument.Adocumentisconsideredreadable
whentheactorsandtherelationshipbetween
themarepresentedconsistentlyandadequately
(Clerehan,etal.,2005).
(4)Metadiscourserefersto“languageaboutthe
textitself”(Clerehan,etal.,2005),andsignalsto
thereaderwhatheissupposedtodowiththe
information,e.g.“Thepurposeofthisdocumentis
togiveyouinformationaboutthetrialcalled(…)”.
(5)Headingsreferto(a)theuseofmainheading
andsubheadingsinadocumentand(b)their
appropriatenessrelatedtothecontent.A
documentisconsideredreadablewhenheadings
givethereaderanimpressionofthemainthemes
andwhentheheadingsandthesubsequent
3contentarethematicallyrelated(Clerehan&
Buchbinder,2006).
(6)Technicalityofthevocabularyrefersto(a)the
useofexpertterminologyinthedocumentand(b)
theuseofexplanationsofexpertterms.A
documentisconsideredreadablewhenthe
terminologyisfamiliartothereaderand/orwhen
explanationsinlaytermsareused
(7)Visualaspectsarelimitedinthepresent
analysistolengthandlayout(i.e.howthetextis
organizedonthepages).Adocumentisconsidered
readablewhenvisualaspects,suchasillustrations,
bulletlistsandothertypographiccuesareusedto
emphasizekeyinformationandtofacilitatethe
reader’sscanningofthedocument(Schriver,
1997).
Procedure
TheanalysisofICDswasperformedinaccordance
withtheframeworkdevelopedbyClerehanand
colleagues(Clerehan,etal.,2005;Clerehan,etal.,
2009),bytheprincipalinvestigatorincollaboration
withthesecondauthor.Theprocedureis
describedbrieflybelow.Theanalysisofeachitem
includedcountingthenumberofidentified
instancesandcomparingthefindingsintheold
andnewICDs.Instancesofuncertaintyconcerning
interpretation,classificationandnamingwere
discussedbytheauthorsuntilconsensuswas
reached.
Thesevencategorieswereanalysedoneatatime,
byreadingallthe20ICDs,andextractingand
markingtherelevantwords,sentencesor
paragraphsdirectlyintheelectronicdocumentsor
onprintedversions.Theidentifiedinstanceswere
registeredintopreliminarytables,and/ora
summarywaswrittenofthefindingsfromeach
category(notshowninResults).Thenumbersof
identifiedinstancesweresummarisedandentered
intotheResulttables.Quotesforexemplifications
ofallthecategorieswereselected.
Theanalysisofgenericstructurewasdoneby
identifyingandnamingthemainthemesinthe
documents.A“theme”wasdefinedaccordingto
theexamplesandfindingspresentedinthestudies
byClerehanandcolleagues(Clerehan,etal.,2005;
Clerehan,etal.,2009).Themesareoverallcontent
units(forinstance"informationaboutstudy
procedures"or"studybackground").Alistofthe
identifiedthemeswascompiledforeachICD.The
listsalsoincludedrepetitionsofthemesandtheir
placementwithindocuments.Theanalysisof
rhetoricalfunctionswasdonebyinvestigatingthe
linguisticandrelationalfunctionregardingeach
identifiedtheme(e.g.wasthetextinformingor
instructing?).TheanalysisofthereaderͲwriterͲ
relationshipwasdoneintwosteps.First,actors
wereidentifiedasvisible(explicit)ornotvisible
(implicit);secondly,thewaysofaddressingand
portrayingthereaderandwriterwereidentified,
andadditionalactorswhowereneitherthereader
northewriterwerealsoidentified.Theanalysisof
technicalityoflanguagewasconductedby
identifyingallwords,phrasesandsentencesin
whichmedicalexpertterminologyorresearch
expertterminologywasused,andtodetermine
whethertheterminologywasexplainedinlay
terms.Theanalysisofmetadiscoursewas
performedbyidentifyingdescriptionsoftheICDs'
purposeand/orfunctionanddirectionsabouthow
toreadandinterpretthetext.Theanalysisof
headingswasdonebyidentifyingthemain
headingsandsubheadingsanddeterminingthe
headings'appropriatenessbycomparingthetopic
intheheadingswiththesubsequentcontent.The
finalitem,visualaspects,wasanalysedbycounting
thenumberofpagesandidentifyingthegraphical
elementsintheICDs.
Finally,thereadabilityoftheidentifiedand
categorisedtextualcharacteristicswasinterpreted
as“morereadable”or“lessreadable”basedon
theoreticalpremisesofreadingcomprehension
thatarethebasisoftheELF.

Results
IGenericstructureoftheICDs
ThemespresentintheICDs
Thethemes,theorderofthethemesandthe
rhetoricalfunctionsinthenewandoldICDsare
presentedinTable1.Onethemewaspresentinall
20ICDs:Informationaboutstudyprocedures,i.e.
practicalimplicationsforthepatients
(examinations,medication,tests,followͲups,and
durationofparticipation).InthenewICDs,three
additionalthemeswereidentifiedinallthe
documents:Purposeofthetrial,Research
procedures(i.e.informationaboutwhatisbeing
doneintheresearchprocessbyactorsotherthan
thepatient,suchasrandomization,datacollection,
Ͳprocessing,Ͳanalyses,Ͳstorage,publication,and
confidentiality)andContactinformation(themes
24inTable1).IntheoldICDs,twoadditional
themeswereidentifiedinalltendocuments:
Backgroundinformation(mostoftenconcerning
thepatient’sdiagnosisandprognosis)and
4informationaboutparticipant’srights(i.e.
voluntarydecision,therighttowithdrawconsent).
Theorderofthethemes
Therewasaclearlackofconsistencyregardingthe
orderinwhichthethemeswerepresentedinall
theICDs.
Theinvitation/requesttoparticipateisanessential
partofareadableICDsinceitisdirectedtowards
themaingoaloftheconsentprocess.Thistheme
hadamorefixedplacementinthenewICDsthan
intheoldones.InthenewICDs,therequestwas
placedinthebeginningofthedocumentorinthe
mainheading.IntheoldICDs,theinvitationwas
placedinthebeginningofthedocumentintwo
cases,inthemiddleofthedocumentintwocases,
andattheendofthedocumentintwocases.
Oneoffewexamplesofacertaindegreeoffixed
orderwasidentifiedintheintroductoryparagraphs
oftheoldICDs,whichinnineofthecases
consistedofpatientstatusand/orbackground
information.
TheintroductoryparagraphsinthenewICDs
showednosuchsimilarities.ThenewICDsopened,
forinstance,withaninvitationtoparticipate,
backgroundinformation,patientstatus,study
procedures,apresentationofthestudy’sname,
informationaboutwhoisresponsibleforthetrial
orarequesttoreadcarefullyandaskquestions.
IIRhetoricalfunctionsintheICDs
Therhetoricalfunctionsrelatedtoeachthemein
theICDsareshowninTable1.Themostfrequent
rhetoricalfunctionintheICDs,botholdandnew,
wastoinform,i.e.topresentfactsandimplications
regardingthereader’s(i.e.cancerpatient’s)
diagnosisandtreatment,abouttheclinicaltrial
andtheimplicationsofparticipating.Mostofthe
ICDsinbothsubsamplesconsistedalmostentirely
ofthefunctiontoinform.
Thesecondmostfrequentrhetoricalfunctionin
theICDswastoexplain(includingelaborationsand
exemplifications).Explanationswerecommonly
identifiedimmediatelyafterinformation.The
followingexcerptillustrateshowexplanations
wereusedtoclarifyapossiblyunfamiliarterm,
“qualityoflife”(explanationunderlinedbyauthor):
“Thepurposeofthisquestionnaireistoinvestigate
thequalityoflifeamongseriouslyillpeople.One
mightsaythatqualityoflifehastodowithone’s
ownexperienceofbothgoodanddifficultaspects
oflife”(41Ͳ91).ThejuxtapositionofinformationͲ
explanationwasfoundbothintheoldandthenew
ICDs;however,itwasslightlymorefrequentinthe
newones(newICDs0–10examplesineach
document(median3½),oldICDs0–4examplesin
eachdocument(median2).
AthirdrhetoricalfunctionpresentintheICDswas
toinstruct,mainlygivingthereaderinstructions
aboutwhattodointhetrial,theparticipants’
responsibilitiesandhowtogiveconsent.
InstructionsweremorefrequentinnewICDsthan
intheoldones(9new/4old).
InstructionsinICDsarewrittenwithaspecific
condition;manyoftheinstructionsareonlyvalidif
thereaderconsents.Theconditionsforthe
instructionsmightbepresentedtothereaderlike
this:Ifyouchoosetoparticipate,itisimportant
thatyoucometothescheduledfollowups
(2007.2125).Severaloftheinstructionsinboththe
oldandnewICDswerewrittenwithoutclarifying
thiscondition.
AfourthrhetoricalfunctionpresentintheICDswas
toaskquestions(6new/7old)Questionswere
mainlyusedforinvitingthereadertoparticipatein
thetrial,forexampleAreyouwillingtohelpus
withanextrabloodtestandfillingina
questionnaire?(65Ͳ87).
IIIReaderandwriter(s)intheICDs
Theanalysisshowedseveralsimilaritiesconcerning
thepresentationofthewriterandreaderintheold
andthenewICDs.Theresultsarepresentedin
Table2.
Thereader
Thereaderwasaddressedintwodifferentwaysin
theICDs.Firstly,thereaderwasaddressed
personallyas“you”innineteenofthetwentyICDs
inthesample,andthepronounwasused
frequentlythroughoutmostofthedocuments.
Secondly,thereaderwasaddressedinthird
person,eitherasmemberofawholegroupof
readers(“Thepatientswillbedividedintotwo
groups”)orasapossiblememberofasubgroupof
thereaders(“Diabeticsmighthavetocheckthe
bloodsugarmoreoften”).Thetwoformsof
addressingwerefrequentlyusedwithinthesame
document(9new/9old).
Further,thereaderwasreferredtointwodifferent
roles:apatientandaneligibletrialparticipant.The
readerwasapatientwhendescribedasaperson
withacancerdiagnosiswhohasundergoneoris
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breastcancerdiseasewhichcurrentlyisnot
suitableforsurgeryorradiation”(21Ͳ87)or
“Requesttoparticipateinastudy(…)among
patientswithuterinecancerwhoreceiveradiation
therapy”(2007.1024).ThreeoftheoldICDswere
initiatedwiththephraseDearpatient.Thereader
wasreferredtoasan(eligible)trialparticipantin
theactualrequesttojointhetrial:[Y]ouarenow
beingaskedifyouarewillingtoparticipateasa
testperson(2006.2144)(5new/6old),andin
phraseswhichshowedthereader’schoiceinthe
consentprocess.Themostfrequentwordingfor
showingthereader’schoicewasIfyou(chooseto)
participate(8new/3old).
Thewriter
ThewriterwaspresentintheICDsthroughthe
personalpronounwe,buttoamuchlesserdegree
thanyoutoaddressthereader(52weversus193
youinthenewICDs,49weversus76youintheold
ones).Aclearreferencefor“we”wasoften
missing.InsomeoftheICDs,thewriterhadsigned
attheendofthedocument(3new/7old).In
threeoftheoldICDs,thewritersignedhisname
aftertheclosingtypicalforpersonalletters“kind
regards”.
“We”couldrefertotheresearchersinchargeof
thetrial.Theresponsibleresearcher/institutions
werepresentedeitherinthebeginningorinthe
endofthedocumentin8newICDs/1oldICD.
Thecontactinformationcouldalsogivethereader
animpressionofthewriteroftheICD.Detailed
contactinformationwasfoundineightofthenew
ICDsandinonlyoneoftheoldones.
ThroughthecontentoftheICDs,thewriter
demonstrateshisroleasanexpertwhoisin
possessionofaconsiderableamountofknowledge
aboutthereader,aboutdiseasesandtreatments,
aboutresearch,andabouttheproceduresinthe
actualtrial.Thewriter’sexpertknowledgeis
associatedwithadualexpertrole:bothamedical
expertandamedicalinvestigator.
Sectionswithoutvisibleactors
TheanalysisofreaderͲwriterrelationshiprevealed
thatseveralsectionsoftheICDswerewritten
withoutavisiblewriter,particularlysections
concerningstudyandresearchprocedures,which
wereoftenwritteninpassivevoice.Through
omittingthesubjectofasentence,thepassive
voicegivestheimpressionofbeingobjective.At
thesametime,itmightalsohidewhois
responsibleforcarryingouttheactionsmentioned
inthedocument.Forinstance,inthesentence“At
thebeginningofthetrial,bonemarrowtestswill
betakentwiceaspartofregularassessmentofthe
disease”(2007.94),thereisnopresentationofwho
willcarryoutthebonemarrowtestsorwhowillbe
treated.
Additionalactors
TheanalysisofreaderͲwriterrelationshiprevealed
thepresenceofactorsotherthan
patient/participantandphysician/investigator.The
numberofadditionalactorsdifferedintheoldand
newICDs.IntheoldICDs,additionalactorswerea
doctorandanurse(infourICDs)andoneortwo
approvingauthorities(ethicalreviewboardand
theNorwegianMedicinesAgencyinthreeICDs).
OneoldICD(34Ͳ88)referredtoapharmaceutical
companyandone(66Ͳ89)referredtoaninsurance
company.ThenewICDscontainedseveralother
actors,forinstanceotherapprovingauthorities
(TheMinistryofHealthandCareServices,The
NorwegianDirectoryofHealth,TheData
Inspectorate,NorwegianSocialScienceData
Services/ThePrivacyOmbudsman).Threemain
categoriesofactorswereidentifiedinthenew
ICDs:(1)thetrial’sresponsibleresearchersor
instances(ahospital,auniversity,health
authorities,adepartment,asection,a
pharmaceuticalcompany,astudygroup,and/or
namedindividuals)(2)otherindividualsinvolvedin
theresearchprocess,and(3)thetrial’ssourcesof
finance.
IVMetadiscourse
AsshowninTable3,metadiscoursewasidentified
inthreenewICDsandinoneoldone.However,
noneoftheseexamplesofmetadiscoursewere
usedtoclarifythemainobjectives,themesor
functionsoftheICD.
VHeadings
MainheadingswereidentifiedineveryICD(Table
3).However,thetypicalmainheadingsdifferedin
thetwosubsamples.Nineofthemainheadingsin
theoldICDswereavariationofPatient
information,whilethemajorityofthemain
headingsinthenewICDsincludedtheword
“request”(7newICDs).
Mostofthesubheadingswerethematically
appropriate.However,aboutafourthofthemdid
notcoveralltheinformationpresentedinthebody
textthatfollowed.Forinstance,thesubheading
VoluntarinesswasusedinfivenewICDs.The
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dealtwithseveralaspectsconcerningparticipants’
rightsmorethanvoluntariness,forinstancethe
righttowithdraw,therighttogetinformation
deleted,andarequesttocollectinformationfrom
theparticipant’sjournal(2007.846).
Afifthofthesubheadingscontainedtermsthat
werepossiblyunfamiliarforapatient/layreader,
suchasBiologicalmaterial(2007.3217)orterms
thatwereusedinadifferentmannerthanthe
readermightbeusedto,forinstancetheheadings
PublicauthoritiesandEthicswhichwerebothused
forparagraphsconcerningapprovalofthetrial
(2007.846,2006.3217).
VITechnicalityofvocabulary
EventhoughthenewICDscontainedmore
explanationsthantheoldones,asshownin
Rhetoricalfunctions,theyalsocontainedmore
examplesofexpertlanguagewithoutexplanations.
Twocategoriesofexpertlanguagewereidentified
intheICDsinthissample:“medicalterminology”
and“researchterminology”.TheICDsusedfor
trialsofnewdrugsdifferedfromtheotherICDs
whenitcametousingexperttermswithout
explainingthem,especiallymedicalterms.Inthe
newdrugtrialICDs,5–22casesofmedicalterms,
phrasesorsentenceswithoutexplanationswere
identified,whilethenumberfortheotherICDs
were010(median2).Regardingtheuseof
researchtermswithoutexplanations,therewasa
markeddifferencebetweenoldandnewICDswith
1–16identifiedcases(median9½)inthenewICDs
and0–3(median1½)casesintheoldones.
VIIVisualaspects
Table3showsthatthelengthofthenewICDswas
betweenoneandfourandahalfpages,whilenone
oftheoldICDswaslongerthanonepage.The
layoutintheoldICDswasquitesimilar,witha
mainheadingandfourtosixparagraphswithout
subheadings.Therewasnouseoflistsorgraphical
elementsintheoldICDs.Overall,thelayoutinthe
newICDswasalsoquitehomogenous,withonly
smalldifferencesintheuseofboldoritalicsinthe
headings.Listswerefoundinonlytwoofthenew
ICDs(anumberedlistin2007.1890andlistswith
bothhyphensandbulletsin2006.2144).No
illustrationswereusedinanyoftheICDs.

Discussion 
TheaimofthepresentstudywastoevaluategoalͲ
orientedreadabilityofICDsbyidentifyingtextual
parametersthatcontributetothetext’s
readability,andtocomparereadabilityinoldand
newICDs.Whiletheanalysisindicatedthatthe
newICDswereinsomewaysmorereadablethan
theoldICDs,theanalysisdidnotshowaclear
tendencytowardsincreasedordecreased
readabilityinnewerICDs.Differenttextual
characteristicscontributingtoincreasedreadability
wereidentifiedinbotholdandnewICDs,suchasa
clearerrelationshipbetweenreaderandwriterin
theoldonesandaclearerpresentationofthe
overallaimofthedocumentinthenewones.
Similarly,characteristicscontributingtodecreased
readabilitywerealsofoundinbothsubsamples,
suchasmuchinformationaboutdiseaseand
treatmentintheoldones(attheexpenseof
researchinformation)andmanyactorspresented
inthenewones.
Readabilityisnotanunambiguousconcept
Severaltextualaspectsmaycontributetoa
readabledocument.Theseaspectsmustbe
appropriateforthespecificsituationandthe
specificparticipantsandtheirgoalsforadocument
tobereadable.Thisimpliesthatthemostrelevant
textualaspectsforenhancingreadabilityinone
situationmaynotbethemostrelevantinanother.
Inthisstudy,weusedtheEvaluativeLinguistic
Framework(ELF)toinvestigatethetextualaspects
thatmightcreatereadabilityintheICDs.One
aspectconsideredtobeofrelevanceforreadability
isthatthereadercanrecogniseagenreinpartby
recognisingthesetofthemespresentedinan
orderthatistypicalforthatgenre(Clerehan&
Buchbinder,2006;Clerehan,etal.,2005;Clerehan,
etal.,2009).However,themainresultsofthe
analysisofICDsshowedthatfewthemescouldbe
identifiedasobligatoryacrosstheICDs,andthe
orderingofthethemeswasinconsistent.Itshould
benotedthattheELFwasdevelopedforthestudy
ofdruginformationleaflets.Theassumptions
aboutgenreandthemerecognitionmightnotbe
asrelevantforICDsasforthedruginformation
leaflets,sincethereaderofanICDisnotlikelyto
havereadanICDpreviously,andthereforeisnot
likelytohavedevelopedanygenericexpectations.
Consequently,readabilityofICDsismore
dependentonalogicalorderofinformationin
ordertoassistthereaderincomprehendinga
genrethatisunfamiliar.Inordertoguidethe
reader,thewriterneedstoconsiderwhichtopics
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beginning,themiddle,andintheendofthe
document.Theinformationwritteninthe
beginningofadocumentisabasisforthereader’s
interpretationoftherestoftheinformation
(Nystrand,1986).Thus,areadableICDwould
presentinformationabouttheoverallpurposeof
thedocumentintheintroduction.ThenewICDs
weremorereadableinthisrespectsinceacrucial
functionofICDs–therequesttothereaderabout
participation–wasplacedinthebeginningofmost
ofthedocuments.Presentingthecontact
informationintheendmightalsocontributeto
increasedreadability,sinceitgivesthereaderan
impressionofwhoisthesenderofthedocument
andalsoisarelevantaddressforwheretoget
answerstoquestionsthatmightariseafterhaving
readtheICDs.Whilethesenderwaspresentinthe
endofmostICDsinbothsubsamples,onlythenew
onesincludedcompletecontactinformation.
ResearchͲorientednewICDs
WhencomparingtheoldandnewICDs,wefound
severaltextualcharacteristicsthatmadethenew
ICDsmoreorientedtowardsresearchasthemain
topic.Thisshouldcontributetoincreasing
readability,sincetheoverallgoalofICDsistoask
thereadertoparticipateinresearchandtoexplain
theimplicationsofbeingaresearchparticipant
comparedtobeingaregularpatient.
Oneofthetextualcharacteristicsthatcontributed
toresearchͲorientationinthenewICDswasthe
typicalmainheading:“Requestyourparticipation
in…”.Therequesttoparticipatewasplacedinthe
beginningofthedocument,andgaveaclear
pictureofwhoisresponsibleforthetrial(for
instancethroughdetailedcontactinformation).
Incontrast,theoldICDsweremoreoriented
towardsthereader’sdiagnosisandtreatment.This
wasobviousinthetypicalmainheadingintheold
ICDs:“Patientinformation”.Furthermore,the
introductionsintheoldICDstypicallypresented
backgroundknowledgeorinformationabout
diagnosisandtreatment.FortheauthorofanICD,
initiatingadocumentwithbackgroundinformation
mightbefamiliar,sinceittypicallycomprisesthe
firstpartofothergenresintheresearch
community,suchasresearcharticlesand
protocols.However,itmightnotnecessarilybean
appropriateintroductioninICDs,whichhavea
patientaudience,sinceitmightindicatethatthe
ICDfirstandforemostisorientedtowardsthe
reader’sdiseaseandtreatmentinsteadofa
documentconcerningresearch,includingarequest
forthereadertoparticipateinthatresearch(even
ifinformationaboutdiagnosisandtreatmentis
probablyconsideredasveryrelevantand
importantformostpatients(Sand,Berger,Loge,
Grønberg,&Kaasa,2008)).
ComplexcastofcharactersinICDs
Theinteractionbetweentheactorswascomplexin
bothsubsamples.Thereader,thewriterandthe
interactionbetweenthemwereoftennotclearly
presented.Thereaderwasaddressedboth
personallyandasamemberofgroups,whilethe
writerwaspresentedasageneral“we”ormissing
completely.
Moreover,boththereaderandwriterofICDswere
ascribeddualroles:thereaderaspatientand
participant,andthewriterasphysicianand
investigator.Thisambiguitymighthinderthe
readerfromgettingaclearpictureofhisownand
others’rolesrelatedtotheICD.Uncertaintyor
confusionaboutwhoisgoingtoperformwhat,and
whatrole(s)thereaderactuallyhascouldreduce
theICDs’readability.InanICD,itshouldbemade
clearthatthereadermustfirstmakeadecision
regardingparticipation,andthenistosignthe
consentforminacorrectmannerifhewishesto
takepart.Inconsenting,thereadermaybesubject
tovariousprecautionsandcommitmentsrelated
tohisroleasparticipant.Alloftheseactionsneed
tobeclearlypresentedtothereader.
Anotheraspectthatmayhinderthereadabilityis
thenumberofotheractorspresentintheICDsthat
thereaderisexpectedtointeractwith,for
examplephysicians,nurses,researchers,
pharmaceuticalcompaniesandauthorities.The
numberofactorspresentedinICDshasincreased
fromtheendofthe1980sto20062007.This
impliesmorerelationshipsthatthereaderhasto
contendwith.Thereadabilitycouldbeincreased
bylimitingthenumberofactorsandbyclarifying
theinteractionbetweenthem.
TheinteractionbetweenreaderandwriterinICDs
isfurtherchallengedbecausetheactualfirst
readersofICDsarenottheeligibletrial
participants,butmembersofethicalreviewboards
thatassesswhetherthemandatoryinformationis
presentintheICDbeforetheeligibleparticipants
receivethedocumentasthesecondreader.The
authorthusattemptstowriteappropriatelyfor
bothaudiences.Someofthedetailsgiveninthe
ICDsappeartobeaddressedtotheethicalreview
board,ratherthanthepatient,forexamplethe
detailsconcerningwhoisinvolvedindata
processing,theactsthatregulateprocessingand
storageofthedata,sourcesoffinanceandallthe
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subjects’evaluationofICDs,wefoundthatlung
cancerpatientseligibleforaclinicaltrialweremost
interestedinpracticalinformationconcerning
whichhospitaltheywouldgotofortreatment,
whowasgoingtoperformthebloodtests,and
whotheymightcontactiftheyhadquestions
(Sand,etal.,2008).ThereadabilityofICDcanbe
improvediftheinformationismoreclearly
directedtowardsthemainreader:theeligibletrial
participant.
Somestudylimitationsneedtobeaddressed.Even
iftheELFisdevelopedforstudiesoftextqualityin
writtenpatientinformationandisabroad
framework,itdoesnotcoverallaspectsthatmight
influencereadability.Duringtheanalysis,
additionalaspectswithinthepredefineditems
wereidentifiedandincludedintotheresults.
Moreover,apotentiallyvastamountofaspects
beyondthetextwouldinfluencereadability,for
instancehealthcondition,cognitivestatus,age,
andpsychologicalstate.Still,thelinguistic
approachinthisstudyhighlightsseveralfactors
relevantforanICD’sreadabilitybeyondthelevelof
traditionalreadabilityindexesandaframework
withpredefineditemswasconsideredastrengthin
aqualitativereadabilityanalysis.
Conclusions
Tosummarize,thereadabilityofanICDmight
increaseifthetextis(1)orientedtowardsresearch
asthemaintopic,(2)orientedtowardstheeligible
trialparticipantasthemainreaderand(3)
presentstheactorsclearly,includingwhowill
performwhichactionssubsequenttothereading
oftheICD.
TheoldICDsappearedaccessiblesincetheirlength
wasonepageorshorterandtheyresembled
personallettersbothinappearanceandinthe
communicationbetweenareaderandasender.
However,theircontentwaslesstothepointthan
thenewICDs.TheoldICDswerenotsufficiently
orientedtowardsaskingthereadertoparticipate
inresearchandexplainingthealternativesand
actionsrelatedtotheresearch.Duringthe20Ͳyear
periodtheICDsinthepresentstudyrepresents,
theregulationsregardingthecontenthave
increased,andthelengthandcomplexityofthe
documentshaveincreasedaccordingly(Berger,et
al.,2009Berger,etal.,2009).However,ICDs’
readabilityhasnotbeenunambiguouslynegatively
affectedbythisdevelopment.Textually,thenew
ICDsaremorelogicallyorganizedandmore
thematicallyadequateaccordingtothegoalofthe
communicationintheinformedconsentprocess:
Toaskthepatienttoparticipateinresearch,to
showhimhisalternativesandhelphimmakehis
voluntarydecisions.

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